{"id": "F01", "question": "目前唯一获FDA批准的CRISPR基因编辑疗法名称是什么？", "answer": "Casgevy(exagamglogene autotemcel)，由Vertex和CRISPR Therapeutics联合开发，2023年12月获FDA批准。", "tags": ["clinical", "regulatory", "CRISPR-Cas9"], "difficulty": "easy", "question_type": "factual", "source": "GEAlmanac", "required_modules": ["almanac"], "key_entities": ["Casgevy", "FDA", "Vertex", "CRISPR Therapeutics"], "evidence_dois": [], "language": "zh"}
{"id": "F02", "question": "SpCas9识别的PAM序列是什么？", "answer": "SpCas9识别的PAM(Protospacer Adjacent Motif)序列为5'-NGG-3'，位于靶序列的3'端下游。", "tags": ["CRISPR-Cas9", "mechanism"], "difficulty": "easy", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["SpCas9", "PAM", "NGG"], "evidence_dois": [], "language": "zh"}
{"id": "F03", "question": "Cas12a(Cpf1)识别的PAM序列是什么？", "answer": "Cas12a识别5'-TTTV-3'(V=A/C/G)的PAM序列，位于靶序列5'端上游，偏好T-rich区域。", "tags": ["Cas12a", "mechanism"], "difficulty": "easy", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["Cas12a", "Cpf1", "TTTV", "PAM"], "evidence_dois": [], "language": "zh"}
{"id": "F04", "question": "腺嘌呤碱基编辑器(ABE)实现什么类型的碱基转换？", "answer": "ABE通过TadA脱氨酶将腺嘌呤(A)脱氨为肌苷(I)，后被读取为鸟嘌呤(G)，实现A·T→G·C碱基对转换。", "tags": ["base_editing", "ABE", "mechanism"], "difficulty": "easy", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["ABE", "TadA", "腺嘌呤", "鸟嘌呤", "A-to-G"], "evidence_dois": [], "language": "zh"}
{"id": "F05", "question": "胞嘧啶碱基编辑器(CBE)实现什么类型的碱基转换？", "answer": "CBE通过APOBEC脱氨酶将胞嘧啶(C)脱氨为尿嘧啶(U)，被读取为胸腺嘧啶(T)，实现C·G→T·A碱基对转换。", "tags": ["base_editing", "CBE", "mechanism"], "difficulty": "easy", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["CBE", "APOBEC", "胞嘧啶", "胸腺嘧啶", "C-to-T"], "evidence_dois": [], "language": "zh"}
{"id": "F06", "question": "Prime Editing系统由哪些核心组件组成？", "answer": "Prime Editing由nCas9-逆转录酶(RT)融合蛋白和pegRNA组成。pegRNA包含spacer序列、引导编辑的引物结合位点(PBS)和逆转录模板(RTT)。", "tags": ["prime_editing", "mechanism"], "difficulty": "easy", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["nCas9", "逆转录酶", "pegRNA", "PBS", "RTT"], "evidence_dois": [], "language": "zh"}
{"id": "F07", "question": "LNP(脂质纳米颗粒)由哪四种主要脂质成分组成？", "answer": "LNP由可电离脂质(核心功能成分)、辅助磷脂(DSPC等,稳定双层)、胆固醇(增强结构稳定性)和PEG-脂质(防止聚集,控制粒径)四种脂质组成。", "tags": ["delivery", "LNP"], "difficulty": "medium", "question_type": "factual", "source": "literature", "required_modules": ["delivery_tree", "retrieval"], "key_entities": ["LNP", "可电离脂质", "DSPC", "胆固醇", "PEG-脂质"], "evidence_dois": [], "language": "zh"}
{"id": "F08", "question": "AAV(腺相关病毒)载体的基因包装容量上限是多少？", "answer": "AAV载体的基因包装容量约为4.7kb(包含ITR在内)。SpCas9编码序列约4.2kb已接近上限，碱基编辑器(~5.2kb)和先导编辑器(~6.3kb)均超出单AAV容量。", "tags": ["delivery", "AAV", "limitations"], "difficulty": "easy", "question_type": "factual", "source": "literature", "required_modules": ["delivery_tree", "retrieval"], "key_entities": ["AAV", "4.7kb", "ITR", "包装容量"], "evidence_dois": [], "language": "zh"}
{"id": "F09", "question": "SpCas9蛋白有多少个氨基酸？", "answer": "SpCas9蛋白由1368个氨基酸组成，分子量约158kDa。包含RuvC和HNH两个核酸酶结构域，分别切割非互补链和互补链。", "tags": ["CRISPR-Cas9", "structure"], "difficulty": "easy", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["SpCas9", "1368", "RuvC", "HNH"], "evidence_dois": [], "language": "zh"}
{"id": "F10", "question": "CRISPR-Cas系统在细菌中的天然功能是什么？", "answer": "CRISPR-Cas是细菌和古菌的适应性免疫系统，通过存储入侵噬菌体的DNA片段(spacer)并利用Cas蛋白识别和切割再次入侵的外源DNA来实现抗病毒防御。", "tags": ["CRISPR-Cas9", "biology"], "difficulty": "easy", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["CRISPR", "adaptive immunity", "spacer", "噬菌体"], "evidence_dois": [], "language": "zh"}
{"id": "F11", "question": "REPAIR系统实现什么类型的RNA编辑？", "answer": "REPAIR(RNA Editing for Programmable A-to-I Replacement)使用dCas13b融合ADAR2脱氨酶结构域，实现RNA水平的A-to-I(读作G)编辑，效率20-50%。", "tags": ["RNA_editing", "REPAIR", "ADAR"], "difficulty": "medium", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["REPAIR", "dCas13b", "ADAR2", "A-to-I"], "evidence_dois": [], "language": "zh"}
{"id": "F12", "question": "Casgevy靶向哪个基因的哪个调控区域？", "answer": "Casgevy靶向BCL11A基因红系特异性增强子，利用CRISPR-Cas9敲除该增强子以抑制BCL11A在红系细胞中的表达，从而重新激活胎儿血红蛋白(HbF)。", "tags": ["clinical", "CRISPR-Cas9", "BCL11A"], "difficulty": "easy", "question_type": "factual", "source": "GEAlmanac", "required_modules": ["almanac"], "key_entities": ["Casgevy", "BCL11A", "增强子", "HbF"], "evidence_dois": [], "language": "zh"}
{"id": "F13", "question": "VERVE-101临床试验靶向哪个基因？", "answer": "VERVE-101靶向PCSK9基因剪接位点，使用腺嘌呤碱基编辑器(ABE)通过LNP递送至肝脏，破坏PCSK9 mRNA剪接从而降低LDL胆固醇。", "tags": ["base_editing", "clinical_trial", "PCSK9"], "difficulty": "easy", "question_type": "factual", "source": "GEAlmanac", "required_modules": ["almanac"], "key_entities": ["VERVE-101", "PCSK9", "ABE", "LNP"], "evidence_dois": [], "language": "zh"}
{"id": "F14", "question": "Intellia的NTLA-2001治疗什么疾病？临床编号是什么？", "answer": "NTLA-2001治疗遗传性转甲状腺素蛋白淀粉样变性(hATTR)，通过LNP递送Cas9 mRNA和靶向TTR基因的sgRNA至肝脏进行基因敲除。临床编号NCT04601051。", "tags": ["CRISPR-Cas9", "in_vivo", "TTR", "clinical_trial"], "difficulty": "easy", "question_type": "factual", "source": "GEAlmanac", "required_modules": ["almanac"], "key_entities": ["NTLA-2001", "hATTR", "TTR", "LNP", "NCT04601051"], "evidence_dois": [], "language": "zh"}
{"id": "F15", "question": "人群中AAV中和抗体的预存率大约是多少？", "answer": "人群中AAV中和抗体预存率约40-70%，具体取决于AAV血清型(AAV2最高可达72%，AAV9约47%)。这严重限制了AAV基因治疗的适用人群范围。", "tags": ["AAV", "immunology", "limitations"], "difficulty": "medium", "question_type": "factual", "source": "literature", "required_modules": ["retrieval", "delivery_tree"], "key_entities": ["AAV", "中和抗体", "40-70%", "AAV2", "AAV9"], "evidence_dois": [], "language": "zh"}
{"id": "F16", "question": "ABE8e相比ABE7.10体外脱氨活性提高了多少倍？", "answer": "ABE8e(Richter 2020 Nature Biotechnol)的TadA-8e脱氨酶体外活性比ABE7.10高约590倍，体内编辑效率从20-40%提升至50-70%。", "tags": ["base_editing", "ABE8e", "improvement"], "difficulty": "medium", "question_type": "factual", "source": "literature", "required_modules": ["retrieval", "almanac"], "key_entities": ["ABE8e", "ABE7.10", "TadA-8e", "590倍"], "evidence_dois": [], "language": "zh"}
{"id": "F17", "question": "PE5max中MLH1dn组件的功能是什么？", "answer": "MLH1dn是错配修复(MMR)通路的显性负性突变体，通过暂时抑制MMR防止细胞修复prime edit产物，将编辑效率提升2-7倍。但暂时抑制MMR可能带来短暂基因组不稳定性。", "tags": ["prime_editing", "PE5max", "MMR"], "difficulty": "medium", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["PE5max", "MLH1dn", "MMR", "错配修复"], "evidence_dois": [], "language": "zh"}
{"id": "F18", "question": "epegRNA如何提高Prime Editing效率？", "answer": "epegRNA在pegRNA 3'端添加结构化RNA基序(如tevopreQ1假结结构)，保护3'延伸区免受核酸外切酶降解，平均提升PE效率3-4倍，且不增加脱靶或indel。", "tags": ["prime_editing", "epegRNA"], "difficulty": "medium", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["epegRNA", "tevopreQ1", "假结", "3-4倍"], "evidence_dois": [], "language": "zh"}
{"id": "F19", "question": "GUIDE-seq脱靶检测使用什么分子标记DSB位点？", "answer": "GUIDE-seq使用短双链寡脱氧核苷酸(dsODN)在CRISPR切割产生的DSB位点整合，再通过定向测序识别所有整合位点，从而发现体内脱靶位点。", "tags": ["off_target", "GUIDE-seq", "methods"], "difficulty": "medium", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["GUIDE-seq", "dsODN", "DSB", "脱靶检测"], "evidence_dois": [], "language": "zh"}
{"id": "F20", "question": "dCas9与野生型Cas9的主要区别是什么？", "answer": "dCas9(dead Cas9)的RuvC和HNH两个核酸酶结构域均含催化失活突变(D10A+H840A)，保留DNA结合能力但丧失切割活性。可作为基因调控平台(CRISPRi/a)使用。", "tags": ["dCas9", "mechanism"], "difficulty": "easy", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["dCas9", "D10A", "H840A", "RuvC", "HNH"], "evidence_dois": [], "language": "zh"}
{"id": "F21", "question": "Casgevy单次治疗费用大约是多少？", "answer": "Casgevy定价约220万美元/次(美国)，是目前最昂贵的基因疗法之一。高昂价格主要源于个体化ex vivo细胞制备流程和清髓预处理的复杂性。", "tags": ["clinical", "cost", "regulatory"], "difficulty": "easy", "question_type": "factual", "source": "GEAlmanac", "required_modules": ["almanac"], "key_entities": ["Casgevy", "220万美元", "ex vivo"], "evidence_dois": [], "language": "zh"}
{"id": "F22", "question": "HDR修复通路在什么细胞周期阶段最为活跃？", "answer": "HDR(同源定向修复)主要在S期和G2期活跃，因为这些阶段有姐妹染色单体作为修复模板。在G1期和非分裂细胞中HDR效率极低，NHEJ占主导。", "tags": ["HDR", "mechanism", "cell_cycle"], "difficulty": "medium", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["HDR", "S期", "G2期", "NHEJ", "细胞周期"], "evidence_dois": [], "language": "zh"}
{"id": "F23", "question": "CRISPR基因编辑技术获得诺贝尔化学奖是哪一年？获奖者是谁？", "answer": "2020年诺贝尔化学奖授予Jennifer Doudna和Emmanuelle Charpentier，表彰她们开发的CRISPR-Cas9基因组编辑工具。", "tags": ["CRISPR-Cas9", "history"], "difficulty": "easy", "question_type": "factual", "source": "GEAlmanac", "required_modules": ["almanac"], "key_entities": ["2020", "Doudna", "Charpentier", "诺贝尔化学奖"], "evidence_dois": [], "language": "zh"}
{"id": "F24", "question": "pegRNA中的PBS和RTT分别指什么？", "answer": "PBS(Primer Binding Site)是引物结合位点，与靶位点切口处3'端互补配对引导逆转录起始。RTT(Reverse Transcriptase Template)是逆转录模板，包含期望的编辑序列供RT合成新DNA。", "tags": ["prime_editing", "pegRNA"], "difficulty": "medium", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["PBS", "RTT", "pegRNA", "逆转录"], "evidence_dois": [], "language": "zh"}
{"id": "F25", "question": "anti-CRISPR蛋白的功能是什么？", "answer": "anti-CRISPR(Acr)蛋白是噬菌体演化出的天然CRISPR抑制因子，可通过阻断PAM识别、抑制crRNA加载或直接结合Cas蛋白活性位点等机制来抑制CRISPR-Cas系统活性。", "tags": ["anti-CRISPR", "mechanism"], "difficulty": "medium", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["anti-CRISPR", "Acr", "噬菌体", "抑制"], "evidence_dois": [], "language": "zh"}
{"id": "C01", "question": "比较SpCas9和Cas12a在PAM序列、切割方式和多重编辑能力上的差异", "answer": "SpCas9: PAM为NGG(3'端)、产生平末端DSB、需逐个设计sgRNA。Cas12a: PAM为TTTV(5'端)、产生5nt粘性末端、自带RNase可加工pre-crRNA阵列天然支持多重编辑。Cas12a更适合AT-rich区域和多基因同时编辑。", "tags": ["Cas9", "Cas12a", "comparison"], "difficulty": "medium", "question_type": "comparison", "source": "literature", "required_modules": ["retrieval", "almanac"], "key_entities": ["SpCas9", "Cas12a", "PAM", "粘性末端", "多重编辑"], "evidence_dois": [], "language": "zh"}
{"id": "C02", "question": "ABE和CBE在编辑类型、适用突变和临床进展上有何不同？", "answer": "ABE实现A→G转换，适用于G→A致病突变的回复(如SCD HBB E6V)；CBE实现C→T转换，适用于引入终止密码子(如PCSK9 W159X)。ABE的RNA脱靶较CBE低，目前ABE临床进展更快(VERVE-101 Phase Ib)。", "tags": ["ABE", "CBE", "comparison"], "difficulty": "medium", "question_type": "comparison", "source": "literature", "required_modules": ["retrieval", "variant_resolver"], "key_entities": ["ABE", "CBE", "A→G", "C→T", "VERVE-101"], "evidence_dois": [], "language": "zh"}
{"id": "C03", "question": "Prime Editing相比Base Editing有哪些优势和劣势？", "answer": "PE优势: 可实现所有12种碱基替换+小插入/缺失、无DSB无脱氨酶故脱靶极低。PE劣势: 效率较低(30-40% vs BE 50-70%)、载荷大(~6.3kb)难以单AAV递送、临床进展落后(2024年才有首个IND)。BE适合特定碱基转换的高效编辑，PE适合灵活但效率要求不极端的场景。", "tags": ["prime_editing", "base_editing", "comparison"], "difficulty": "hard", "question_type": "comparison", "source": "literature", "required_modules": ["retrieval", "almanac"], "key_entities": ["Prime Editing", "Base Editing", "效率", "载荷", "脱靶"], "evidence_dois": [], "language": "zh"}
{"id": "C04", "question": "LNP和AAV递送系统在基因编辑中的主要优劣对比", "answer": "LNP优势: 无基因组整合风险、可重复给药、瞬时表达降低脱靶、制造简单；LNP劣势: 主要靶向肝脏、大分子包裹效率低。AAV优势: 组织嗜性多样(不同血清型)、长期表达、临床经验丰富；AAV劣势: 容量仅4.7kb、免疫原性高(预存抗体40-70%)、仅能给药一次、高剂量肝毒性。", "tags": ["LNP", "AAV", "delivery", "comparison"], "difficulty": "medium", "question_type": "comparison", "source": "literature", "required_modules": ["delivery_tree", "retrieval"], "key_entities": ["LNP", "AAV", "免疫原性", "重复给药", "包装容量"], "evidence_dois": [], "language": "zh"}
{"id": "C05", "question": "体内(in vivo)和离体(ex vivo)基因编辑各适用于什么场景？", "answer": "Ex vivo适用于可获取的细胞类型(HSC→血液病、T细胞→CAR-T)，优势是可质控但需清髓；In vivo适用于不可取出组织(肝脏→LNP静脉注射、眼→局部AAV)，优势是一次给药但编辑效率和脱靶更难控制。趋势：肝脏in vivo已成熟，非肝组织是下一前沿。", "tags": ["in_vivo", "ex_vivo", "comparison"], "difficulty": "medium", "question_type": "comparison", "source": "expert_knowledge", "required_modules": ["delivery_tree", "retrieval"], "key_entities": ["in vivo", "ex vivo", "HSC", "LNP", "清髓"], "evidence_dois": [], "language": "zh"}
{"id": "C06", "question": "CRISPRi和CRISPRa的原理和应用有何不同？", "answer": "CRISPRi: dCas9融合KRAB抑制域→靶向TSS附近→H3K9me3表观沉默→基因沉默80-99%。CRISPRa: dCas9融合VP64/VPR激活域→上调表达10-1000倍。两者均不切割DNA，效果可逆。CRISPRi用于功能缺失筛选，CRISPRa用于功能获得筛选。", "tags": ["CRISPRi", "CRISPRa", "epigenome", "comparison"], "difficulty": "medium", "question_type": "comparison", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["CRISPRi", "CRISPRa", "dCas9", "KRAB", "VP64"], "evidence_dois": [], "language": "zh"}
{"id": "C07", "question": "CRISPR-Cas9、TALEN和ZFN三代基因编辑工具的主要区别", "answer": "ZFN(第一代): 锌指蛋白识别DNA+FokI切割，设计困难成本高。TALEN(第二代): TAL效应子识别+FokI切割，比ZFN更灵活但蛋白质大。CRISPR-Cas9(第三代): RNA引导识别+Cas9切割，设计简单(仅需20nt sgRNA)、成本低、适合多重编辑。CRISPR已基本取代前两代。", "tags": ["CRISPR", "TALEN", "ZFN", "comparison"], "difficulty": "medium", "question_type": "comparison", "source": "literature", "required_modules": ["retrieval", "almanac"], "key_entities": ["CRISPR", "TALEN", "ZFN", "FokI", "sgRNA"], "evidence_dois": [], "language": "zh"}
{"id": "C08", "question": "ssODN和dsDNA作为HDR修复模板的效率差异", "answer": "ssODN(单链寡核苷酸)效率比dsDNA(双链DNA)高5-10倍，因为ssODN更易被RAD51加载至修复位点且不易随机整合。但ssODN长度受限(~200nt)，仅适合小范围编辑；大片段敲入(>1kb)仍需dsDNA或质粒模板。", "tags": ["HDR", "template", "comparison"], "difficulty": "medium", "question_type": "comparison", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["ssODN", "dsDNA", "HDR", "RAD51", "5-10倍"], "evidence_dois": [], "language": "zh"}
{"id": "C09", "question": "GUIDE-seq和CIRCLE-seq脱靶检测方法的灵敏度和适用性比较", "answer": "GUIDE-seq: 体内检测(需转染活细胞)，灵敏度高，最接近真实脱靶谱，被视为金标准；假阳性低但需要活细胞系。CIRCLE-seq: 体外全基因组环化DNA切割检测，灵敏度极高(可检测0.01%频率脱靶)，但假阳性率高(很多体外脱靶在体内不发生)，需实验验证。", "tags": ["off_target", "GUIDE-seq", "CIRCLE-seq", "comparison"], "difficulty": "hard", "question_type": "comparison", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["GUIDE-seq", "CIRCLE-seq", "灵敏度", "假阳性", "金标准"], "evidence_dois": [], "language": "zh"}
{"id": "C10", "question": "RNA编辑与DNA编辑在安全性和持久性方面的对比", "answer": "RNA编辑优势: 可逆(不改变基因组)、零基因组脱靶、无染色体异常、可重复给药。劣势: 效果短暂需持续给药、全转录组脱靶(ADAR过表达致0.01-1% A-to-I)、效率波动30-80%。DNA编辑: 永久改变一劳永逸，但不可逆且有基因组安全性隐患。", "tags": ["RNA_editing", "DNA_editing", "safety", "comparison"], "difficulty": "hard", "question_type": "comparison", "source": "literature", "required_modules": ["retrieval", "safety_firewall"], "key_entities": ["RNA编辑", "DNA编辑", "可逆性", "脱靶", "ADAR"], "evidence_dois": [], "language": "zh"}
{"id": "C11", "question": "碱基编辑与HDR精确修复在治疗点突变疾病时的比较", "answer": "碱基编辑: 无DSB、效率高(50-70%)、不依赖细胞周期、但仅限A→G或C→T转换。HDR修复: 可实现任意序列修改(all 12 substitutions+insertion+deletion)、但效率低(通常<10%在HSC中)、仅S/G2期活跃、NHEJ竞争。对适用的点突变，碱基编辑显著优于HDR。", "tags": ["base_editing", "HDR", "comparison"], "difficulty": "medium", "question_type": "comparison", "source": "literature", "required_modules": ["retrieval", "variant_resolver"], "key_entities": ["碱基编辑", "HDR", "效率", "DSB", "细胞周期"], "evidence_dois": [], "language": "zh"}
{"id": "C12", "question": "mRNA递送和RNP(蛋白-RNA复合物)递送基因编辑组件的比较", "answer": "mRNA递送: 通过LNP包裹，适合体内系统给药(如NTLA-2001)，但需细胞翻译产生蛋白，Cas9表达持续12-24h。RNP递送: 蛋白质直接与sgRNA复合，通过电穿孔进入，即时活性，12h内降解，脱靶更低；但不适合体内全身给药，主要用于ex vivo。", "tags": ["mRNA", "RNP", "delivery", "comparison"], "difficulty": "medium", "question_type": "comparison", "source": "literature", "required_modules": ["delivery_tree", "retrieval"], "key_entities": ["mRNA", "RNP", "LNP", "电穿孔", "半衰期"], "evidence_dois": [], "language": "zh"}
{"id": "C13", "question": "Casgevy和Lyfgenia在治疗β-地中海贫血时的策略差异", "answer": "Casgevy: CRISPR-Cas9敲除BCL11A增强子→重激活HbF→功能补偿。Lyfgenia(lovotibeglogene autotemcel): 慢病毒载体将功能性βA-T87Q-globin基因随机整合至HSC基因组→直接补充β-globin。策略根本不同：前者是编辑，后者是基因添加。Casgevy更精准但依赖HbF代偿，Lyfgenia有插入致癌风险。", "tags": ["Casgevy", "Lyfgenia", "thalassemia", "comparison"], "difficulty": "hard", "question_type": "comparison", "source": "GEAlmanac", "required_modules": ["almanac", "retrieval"], "key_entities": ["Casgevy", "Lyfgenia", "BCL11A", "β-globin", "慢病毒"], "evidence_dois": [], "language": "zh"}
{"id": "C14", "question": "PEmax相比PE2的主要改进有哪些？", "answer": "PEmax改进：1)密码子优化的逆转录酶提高蛋白表达; 2)优化的NLS(核定位信号)提高核内定位; 3)优化的linker连接nCas9与RT。配合nicking guide(PE3)和MLH1dn(PE5)可达HEK293T中60%+效率。PE2(第一代)效率通常仅5-15%。", "tags": ["prime_editing", "PEmax", "PE2", "comparison"], "difficulty": "medium", "question_type": "comparison", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["PEmax", "PE2", "密码子优化", "NLS", "linker"], "evidence_dois": [], "language": "zh"}
{"id": "C15", "question": "慢病毒基因整合和CRISPR定点敲入在基因治疗中的比较", "answer": "慢病毒整合: 半随机(偏好转录活跃区)，可携带大片段，但有插入致突变风险(如X-SCID试验中的白血病)；CRISPR定点敲入: 利用HDR在特定位点精准插入，消除随机整合风险，但效率低(HSC中<10%)。AAV供体模板可提高敲入效率但有AAV限制。", "tags": ["lentivirus", "CRISPR", "knockin", "comparison"], "difficulty": "medium", "question_type": "comparison", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["慢病毒", "CRISPR", "定点敲入", "HDR", "插入致突变"], "evidence_dois": [], "language": "zh"}
{"id": "C16", "question": "Cas13与Cas9的作用靶标和切割特征有何根本区别？", "answer": "Cas9: 靶向双链DNA，识别PAM后解旋+切割→DSB，永久改变基因组。Cas13: 靶向单链RNA，识别PFS后切割靶RNA，效果可逆且不改变DNA。Cas13激活后有collateral cleavage(旁切非靶RNA)，在诊断中被利用(SHERLOCK)，在治疗中需控制。", "tags": ["Cas9", "Cas13", "RNA", "comparison"], "difficulty": "medium", "question_type": "comparison", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["Cas9", "Cas13", "DNA", "RNA", "collateral"], "evidence_dois": [], "language": "zh"}
{"id": "C17", "question": "电穿孔和LNP在ex vivo细胞编辑中的优劣比较", "answer": "电穿孔: 适用于所有细胞类型、递送效率高(>80% RNP)、可精确控制剂量，但导致细胞损伤影响活力(通常降低20-30%)且不适合体内。LNP: 细胞毒性低、可体内使用，但对非肝脏悬浮细胞(如HSC/T cell)转染效率偏低。目前ex vivo标准是电穿孔RNP。", "tags": ["electroporation", "LNP", "ex_vivo", "comparison"], "difficulty": "medium", "question_type": "comparison", "source": "literature", "required_modules": ["delivery_tree", "retrieval"], "key_entities": ["电穿孔", "LNP", "RNP", "细胞活力"], "evidence_dois": [], "language": "zh"}
{"id": "C18", "question": "SHERLOCK和DETECTR两种CRISPR诊断平台的比较", "answer": "SHERLOCK: 基于Cas13a，靶向RNA，需RPA+T7体外转录步骤，灵敏度达attomole；DETECTR: 基于Cas12a，靶向DNA，只需RPA扩增，流程更简单。两者都利用collateral cleavage切割荧光报告分子。SHERLOCK可检测RNA病毒(如SARS-CoV-2)，DETECTR更适合DNA靶标(如HPV)。", "tags": ["SHERLOCK", "DETECTR", "diagnostics", "comparison"], "difficulty": "medium", "question_type": "comparison", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["SHERLOCK", "DETECTR", "Cas13a", "Cas12a", "RPA"], "evidence_dois": [], "language": "zh"}
{"id": "C19", "question": "enAsCas12a和SpCas9在PAM灵活性和编辑窗口上的对比", "answer": "enAsCas12a(engineered Cas12a): PAM放宽为TTYN/VTTV等，覆盖更多位点，在AT-rich区优势明显，切割产生粘性末端。SpCas9: PAM为NGG，在GC-rich区覆盖好，编辑窗口更窄更精确。SpCas9-NG/xCas9等变体放宽PAM但活性略降。总体SpCas9临床数据更丰富。", "tags": ["enAsCas12a", "SpCas9", "PAM", "comparison"], "difficulty": "medium", "question_type": "comparison", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["enAsCas12a", "SpCas9", "PAM", "TTYN", "NGG"], "evidence_dois": [], "language": "zh"}
{"id": "C20", "question": "Compare base editing and prime editing for treating sickle cell disease", "answer": "Base editing (ABE): Can directly convert HBB E6V mutation (GTG→GAG) via A→G, efficiency 58-68% in HSCs, but limited by bystander edits in editing window. Prime editing: More flexible, can install any point mutation without DSB, very low off-targets, but lower efficiency (30-40%) and large payload (~6.3kb) limits delivery. ABE is preferred for this specific mutation due to higher efficiency.", "tags": ["base_editing", "prime_editing", "sickle_cell", "comparison"], "difficulty": "hard", "question_type": "comparison", "source": "literature", "required_modules": ["retrieval", "variant_resolver"], "key_entities": ["ABE", "Prime Editing", "HBB", "E6V", "efficiency"], "evidence_dois": [], "language": "en"}
{"id": "C21", "question": "AAV8和AAV9在组织嗜性方面有何差异？", "answer": "AAV8主要嗜性为肝脏和肌肉(通过LamR受体)，是肝脏基因治疗的常用血清型。AAV9能跨越血脑屏障(BBB)，嗜性包括CNS、心脏和肝脏，是唯一获批用于SMA治疗(Zolgensma)的血清型。AAV9全身高剂量给药有肝毒性风险。", "tags": ["AAV8", "AAV9", "tissue_tropism", "comparison"], "difficulty": "medium", "question_type": "comparison", "source": "literature", "required_modules": ["delivery_tree", "retrieval"], "key_entities": ["AAV8", "AAV9", "肝脏", "血脑屏障", "Zolgensma"], "evidence_dois": [], "language": "zh"}
{"id": "C22", "question": "What are the key differences between CRISPR-Cas9 knockout and CRISPRi silencing?", "answer": "Cas9 KO: Creates DSB→NHEJ→indels→permanent gene disruption. Irreversible, risks off-target DSBs, large deletions, chromothripsis. CRISPRi: dCas9-KRAB induces H3K9me3→transcriptional silencing without DNA changes. Reversible, zero genomic off-targets, but requires sustained dCas9 expression. CRISPRi preferred for functional screens; Cas9 KO for therapeutic permanent editing.", "tags": ["CRISPR-Cas9", "CRISPRi", "comparison"], "difficulty": "medium", "question_type": "comparison", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["Cas9", "CRISPRi", "dCas9", "KRAB", "H3K9me3"], "evidence_dois": [], "language": "en"}
{"id": "C23", "question": "碱基编辑在DNA水平和RNA水平的脱靶特征对比", "answer": "DNA脱靶: CBE/ABE在sgRNA非特异性结合位点产生碱基替换，频率通常<0.1%，可通过高保真Cas9降低。RNA脱靶: 脱氨酶(特别是CBE的APOBEC和ABE的TadA)可作用于转录组RNA，CBE RNA脱靶率更高，ABE8e-V106W变体显著降低RNA脱靶。两种脱靶机制独立，需分别检测。", "tags": ["base_editing", "off_target", "comparison"], "difficulty": "hard", "question_type": "comparison", "source": "literature", "required_modules": ["retrieval", "safety_firewall"], "key_entities": ["DNA脱靶", "RNA脱靶", "CBE", "ABE", "V106W"], "evidence_dois": [], "language": "zh"}
{"id": "C24", "question": "RESCUE和REPAIR RNA编辑系统的比较", "answer": "REPAIR: dCas13b-ADAR2dd实现A→I(读作G)编辑，利用天然ADAR脱氨活性，效率20-50%。RESCUE: 通过定向进化ADAR2dd获得C→U编辑能力，扩展了RNA编辑类型，但效率较低且脱靶更高。两者均需外源Cas13+融合蛋白表达，载荷大。当前临床更倾向内源ADAR招募策略(不需递送大蛋白)。", "tags": ["REPAIR", "RESCUE", "RNA_editing", "comparison"], "difficulty": "hard", "question_type": "comparison", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["REPAIR", "RESCUE", "ADAR2", "A→I", "C→U"], "evidence_dois": [], "language": "zh"}
{"id": "C25", "question": "CRISPR基因编辑在治疗领域和农业领域的监管差异", "answer": "治疗领域: 严格的临床试验流程(IND→Phase I/II/III→BLA/MAA)，需证明安全性和有效性，审批周期10+年。农业领域: SDN-1(无外源DNA)编辑产品在美国/日本/阿根廷不作为GMO监管，审批快速；欧盟2023年提案放宽但仍在讨论中。农业去监管化是全球趋势。", "tags": ["regulation", "agriculture", "therapy", "comparison"], "difficulty": "medium", "question_type": "comparison", "source": "expert_knowledge", "required_modules": ["retrieval", "patent"], "key_entities": ["SDN-1", "GMO", "FDA", "EMA", "监管"], "evidence_dois": [], "language": "zh"}
{"id": "M01", "question": "描述Cas9识别并切割靶DNA的分子过程", "answer": "1)sgRNA与Cas9结合形成核糖核蛋白复合物; 2)Cas9扫描DNA寻找PAM(NGG); 3)识别PAM后解旋DNA，sgRNA的seed区(PAM近端8-12nt)与靶链配对形成R-loop; 4)完全配对后，HNH结构域切割互补链，RuvC结构域切割非互补链; 5)产生平末端DSB(PAM上游3bp处)。", "tags": ["CRISPR-Cas9", "mechanism"], "difficulty": "medium", "question_type": "mechanism", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["Cas9", "PAM", "R-loop", "HNH", "RuvC", "DSB"], "evidence_dois": [], "language": "zh"}
{"id": "M02", "question": "ABE中TadA脱氨酶的工作机制是什么？", "answer": "TadA(tRNA腺苷脱氨酶)原本作用于tRNA的A34位。ABE中，进化后的TadA*连接于nCas9(D10A)，当sgRNA引导复合物结合靶位点后，非编辑链(R-loop中暴露的ssDNA)上的腺嘌呤被TadA*脱氨为肌苷(I)。nCas9在互补链切口促进细胞用G替换对面的T，最终完成A·T→G·C转换。", "tags": ["base_editing", "ABE", "TadA", "mechanism"], "difficulty": "hard", "question_type": "mechanism", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["TadA", "nCas9", "脱氨", "肌苷", "R-loop"], "evidence_dois": [], "language": "zh"}
{"id": "M03", "question": "详述Prime Editing从sgRNA结合到编辑完成的完整分子机制", "answer": "1)pegRNA引导nCas9(H840A)-RT结合靶位点; 2)nCas9切割PAM链(非编辑链)产生3'切口; 3)pegRNA的PBS与切口处暴露的3'端互补配对; 4)RT以pegRNA的RTT为模板逆转录合成含目标编辑的新DNA链; 5)新合成链取代原序列(flap equilibration); 6)细胞DNA修复机制移除原5'flap并连接新链; 7)第二个nicking guide(PE3)在对面链切口促进编辑链拷贝。", "tags": ["prime_editing", "mechanism"], "difficulty": "hard", "question_type": "mechanism", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["pegRNA", "nCas9", "RT", "PBS", "RTT", "flap"], "evidence_dois": [], "language": "zh"}
{"id": "M04", "question": "HDR和NHEJ修复通路为何存在竞争？NHEJ如何抑制HDR？", "answer": "DSB后53BP1快速募集至断裂位点，阻止末端切除(end resection)，引导NHEJ快速修复(全细胞周期活跃)。HDR需要BRCA1/CtIP介导的5'→3'末端切除产生ssDNA overhang，再由RAD51加载寻找同源模板。53BP1阻断末端切除是NHEJ抑制HDR的关键节点。抑制53BP1(如i53)或DNA-PKcs(M3814)可提升HDR比例。", "tags": ["HDR", "NHEJ", "mechanism", "DNA_repair"], "difficulty": "medium", "question_type": "mechanism", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["53BP1", "BRCA1", "CtIP", "RAD51", "DNA-PKcs"], "evidence_dois": [], "language": "zh"}
{"id": "M05", "question": "LNP包裹mRNA进入靶细胞并释放的分子过程", "answer": "1)可电离脂质在酸性pH下带正电，与mRNA静电结合形成核心; 2)PEG-脂质层防止体内聚集，延长循环时间; 3)LNP经ApoE吸附后通过LDL受体介导的内吞进入肝细胞; 4)进入内体后，内体酸化(pH~5)使可电离脂质质子化→与内体膜融合→内体逃逸; 5)mRNA释放至细胞质被核糖体翻译产生Cas9/BE蛋白。", "tags": ["LNP", "delivery", "mechanism"], "difficulty": "medium", "question_type": "mechanism", "source": "literature", "required_modules": ["delivery_tree", "retrieval"], "key_entities": ["LNP", "可电离脂质", "ApoE", "内体逃逸", "LDL受体"], "evidence_dois": [], "language": "zh"}
{"id": "M06", "question": "ADAR介导的A-to-I RNA编辑的天然机制是什么？", "answer": "ADAR(Adenosine Deaminase Acting on RNA)识别双链RNA(dsRNA)结构，将dsRNA中的腺苷(A)水解脱氨为肌苷(I)。I在翻译中被读作G，从而改变密码子含义。人体有ADAR1和ADAR2两个活性家族成员。ADAR1主要编辑Alu重复序列防止先天免疫激活，ADAR2主要编辑特定mRNA(如GluR-B Q/R位点)。", "tags": ["ADAR", "RNA_editing", "mechanism"], "difficulty": "medium", "question_type": "mechanism", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["ADAR", "dsRNA", "腺苷", "肌苷", "Alu"], "evidence_dois": [], "language": "zh"}
{"id": "M07", "question": "CRISPRi如何通过表观遗传修饰实现基因沉默？", "answer": "CRISPRi使用dCas9(催化失活)融合KRAB(Krüppel-associated box)转录抑制域。sgRNA引导dCas9-KRAB结合至基因TSS(转录起始位点)附近。KRAB招募KAP1/SETDB1复合物催化H3K9me3修饰，形成异染色质，物理阻断RNA PolII延伸和转录因子结合，实现80-99%的转录沉默。效果在几天内建立，停止dCas9表达后可逆。", "tags": ["CRISPRi", "epigenetics", "mechanism"], "difficulty": "medium", "question_type": "mechanism", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["dCas9", "KRAB", "H3K9me3", "TSS", "KAP1"], "evidence_dois": [], "language": "zh"}
{"id": "M08", "question": "Cas13的collateral cleavage(旁切活性)是如何产生的？", "answer": "Cas13的两个HEPN核酸酶结构域在未结合靶RNA时处于抑制状态。当crRNA引导Cas13识别并结合靶RNA后，构象变化激活HEPN域，切割靶RNA。关键是：激活后的HEPN域变为非特异性RNase，可切割附近的任何ssRNA(collateral cleavage)。在细菌中此机制导致细胞休眠防止噬菌体扩散；在哺乳细胞中此效应较弱。", "tags": ["Cas13", "collateral_cleavage", "mechanism"], "difficulty": "hard", "question_type": "mechanism", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["Cas13", "HEPN", "collateral", "ssRNA", "crRNA"], "evidence_dois": [], "language": "zh"}
{"id": "M09", "question": "BCL11A增强子敲除如何重新激活胎儿血红蛋白(HbF)？", "answer": "BCL11A是HBG1/HBG2(γ-globin)基因的转录抑制因子，在出生后抑制HbF表达并促进成人HbA(β-globin)表达(血红蛋白开关)。敲除红系特异性增强子(+58区域)不影响其他组织中BCL11A功能，但特异性解除红系中的γ-globin抑制→HbF重新高表达→代偿缺陷的β-globin功能(SCD/TDT)。", "tags": ["BCL11A", "HbF", "mechanism"], "difficulty": "medium", "question_type": "mechanism", "source": "literature", "required_modules": ["retrieval", "almanac"], "key_entities": ["BCL11A", "HbF", "HBG1", "γ-globin", "增强子"], "evidence_dois": [], "language": "zh"}
{"id": "M10", "question": "PAM近端seed区域错配为何比远端错配更影响Cas9特异性？", "answer": "sgRNA的seed区(PAM近端8-12nt)是R-loop形成的起始位点。Cas9首先在PAM端开始DNA解旋和配对，seed区的匹配决定R-loop能否稳定建立。seed区错配导致R-loop无法完全形成→Cas9解离→不切割。而PAM远端错配可被容忍(R-loop已稳定)，仍可能导致切割→成为脱靶来源。", "tags": ["CRISPR-Cas9", "specificity", "mechanism"], "difficulty": "hard", "question_type": "mechanism", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["seed区", "R-loop", "PAM", "特异性", "脱靶"], "evidence_dois": [], "language": "zh"}
{"id": "M11", "question": "CBE中UGI组件的作用机制是什么？", "answer": "CBE将胞嘧啶脱氨为尿嘧啶(U)后，细胞碱基切除修复(BER)中的UNG(尿嘧啶-DNA糖基化酶)会识别并切除U→恢复为C→编辑失败。UGI(Uracil Glycosylase Inhibitor)通过结合并抑制UNG，保护U不被切除，使DNA复制时U被读取为T→完成C→T编辑。CBE4包含两个UGI拷贝进一步提高保护效率。", "tags": ["CBE", "UGI", "UNG", "mechanism"], "difficulty": "medium", "question_type": "mechanism", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["UGI", "UNG", "尿嘧啶", "BER", "CBE"], "evidence_dois": [], "language": "zh"}
{"id": "M12", "question": "Explain the molecular mechanism of CIRCLE-seq for off-target detection", "answer": "CIRCLE-seq works by: 1) Shearing genomic DNA into ~500bp fragments; 2) Circularizing fragments via intramolecular ligation; 3) Degrading linear DNA with exonuclease→only circles remain; 4) Treating circles with Cas9+sgRNA in vitro→circles cut at on/off-target sites become linear; 5) Selectively sequencing linearized molecules (only cut sites). The circularization step eliminates uncleaved DNA, enabling extremely sensitive detection of any Cas9 cleavage site genome-wide.", "tags": ["CIRCLE-seq", "off_target", "mechanism"], "difficulty": "hard", "question_type": "mechanism", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["CIRCLE-seq", "circularization", "exonuclease", "linearization"], "evidence_dois": [], "language": "en"}
{"id": "M13", "question": "MMR(错配修复)通路如何影响Prime Editing效率？", "answer": "PE合成的新DNA 3'flap与原链形成异源双链(heteroduplex)含有错配。MMR通路(MLH1/MSH2/MSH6)识别错配后，约50%概率修复回原序列(逆转编辑)。PE4/PE5引入MLH1dn暂时抑制MMR，使异源双链在下次复制时直接传递编辑，效率提升2-7倍。但MLH1dn暂时提高自发突变率。", "tags": ["prime_editing", "MMR", "mechanism"], "difficulty": "hard", "question_type": "mechanism", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["MMR", "MLH1", "heteroduplex", "PE4", "PE5"], "evidence_dois": [], "language": "zh"}
{"id": "M14", "question": "可电离脂质在LNP中的pH依赖行为及其功能意义", "answer": "可电离脂质的pKa设计在6.0-6.5之间。在生理pH(7.4)下呈中性→不与血清蛋白非特异结合→延长循环。在内体酸性pH(5.0-6.0)下质子化带正电→与内体膜带负电的磷脂相互作用→形成非双层结构(hexagonal phase)→破坏内体膜→mRNA释放至细胞质。这一pH开关机制是LNP递送效率的核心。", "tags": ["LNP", "ionizable_lipid", "mechanism"], "difficulty": "medium", "question_type": "mechanism", "source": "literature", "required_modules": ["delivery_tree", "retrieval"], "key_entities": ["可电离脂质", "pKa", "内体酸化", "hexagonal phase"], "evidence_dois": [], "language": "zh"}
{"id": "M15", "question": "Chromothripsis在CRISPR-Cas9编辑中的发生机制", "answer": "CRISPR产生DSB后，在极少数细胞中，含DSB的染色体片段可能被错误分配进微核(micronuclei)。微核中的DNA复制和修复严重受损→染色体碎裂成数十至数百片段→片段随机重新连接(NHEJ mediated)→产生大规模基因组重排(chromothripsis)。这是一种小概率但灾难性的事件，碱基编辑和先导编辑可避免。", "tags": ["chromothripsis", "safety", "mechanism"], "difficulty": "hard", "question_type": "mechanism", "source": "literature", "required_modules": ["retrieval", "safety_firewall"], "key_entities": ["chromothripsis", "微核", "DSB", "基因组重排"], "evidence_dois": [], "language": "zh"}
{"id": "M16", "question": "nCas9(D10A)为何能降低脱靶但维持on-target编辑效率？", "answer": "nCas9(D10A)仅保留HNH结构域活性→只切割一条链(nick)。单独的nick由高保真BER/NER快速修复→不产生indel。在碱基编辑中：nCas9的nick引导细胞优先修复非编辑链→保留脱氨酶产生的编辑。在off-target位点，单nick被无误修复→不产生突变。在on-target位点，nick+脱氨协同→高效编辑。", "tags": ["nCas9", "specificity", "mechanism"], "difficulty": "hard", "question_type": "mechanism", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["nCas9", "D10A", "nick", "HNH", "脱靶"], "evidence_dois": [], "language": "zh"}
{"id": "M17", "question": "HITI(同源非依赖性靶向插入)的分子机制", "answer": "HITI利用NHEJ而非HDR实现定向插入：1)Cas9在基因组靶位点和供体质粒上同时切割; 2)线性化的供体片段通过NHEJ在基因组DSB处插入; 3)供体设计为正向插入时破坏sgRNA靶位点→不再被切割(自限)，反向插入恢复靶位点→会被再次切割移除→富集正向插入。HITI可在非分裂细胞中工作，适用于post-mitotic neurons。", "tags": ["HITI", "NHEJ", "knockin", "mechanism"], "difficulty": "hard", "question_type": "mechanism", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["HITI", "NHEJ", "定向插入", "非分裂细胞"], "evidence_dois": [], "language": "zh"}
{"id": "M18", "question": "R-loop在CRISPR编辑中的形成与稳定过程", "answer": "R-loop是CRISPR-Cas识别靶位点的核心中间体：1)Cas9结合PAM(NGG)→局部解旋DNA; 2)sgRNA seed区(PAM端8-12nt)与靶链互补配对→形成初始RNA:DNA杂合双链; 3)配对从seed向PAM远端延伸; 4)完全匹配(~20nt)后R-loop稳定→触发Cas9构象变化→激活切割活性。部分匹配(off-target)的R-loop不稳定→可能解离或以低效率切割。", "tags": ["R-loop", "CRISPR-Cas9", "mechanism"], "difficulty": "medium", "question_type": "mechanism", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["R-loop", "seed", "PAM", "RNA:DNA杂合", "构象变化"], "evidence_dois": [], "language": "zh"}
{"id": "M19", "question": "碱基编辑器的编辑窗口由什么因素决定？", "answer": "编辑窗口由脱氨酶与nCas9的空间关系决定：1)脱氨酶连接在nCas9 N端→可接触R-loop中暴露的ssDNA特定位置; 2)SpCas9 ABE典型窗口为位置4-8(PAM远端起算); 3)linker长度影响窗口宽窄; 4)TadA变体影响底物偏好(ABE8e窗口更集中在4-7); 5)SaCas9版本BE窗口与SpCas9不同。靶碱基需位于窗口内才能被高效编辑。", "tags": ["base_editing", "editing_window", "mechanism"], "difficulty": "medium", "question_type": "mechanism", "source": "literature", "required_modules": ["retrieval", "variant_resolver"], "key_entities": ["编辑窗口", "脱氨酶", "linker", "位置4-8"], "evidence_dois": [], "language": "zh"}
{"id": "M20", "question": "Cas12a自加工pre-crRNA的分子机制", "answer": "Cas12a(Cpf1)具有独特的RNase活性(独立于DNase活性)，可直接处理CRISPR阵列转录产物。一条pre-crRNA阵列可含多个spacer+direct repeat(DR)，Cas12a识别DR中的发卡结构并在特定位点切割→释放成熟crRNA。这使得单一启动子驱动的多crRNA阵列可被一个Cas12a处理→天然支持多重编辑，无需分别表达每个sgRNA。", "tags": ["Cas12a", "crRNA", "processing", "mechanism"], "difficulty": "medium", "question_type": "mechanism", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["Cas12a", "pre-crRNA", "RNase", "direct repeat", "多重编辑"], "evidence_dois": [], "language": "zh"}
{"id": "CL01", "question": "VERVE-101 Phase Ib临床试验的设计和初步结果如何？", "answer": "VERVE-101(NCT05398029)：单次LNP静脉注射ABE靶向肝脏PCSK9剪接位点，治疗杂合家族性高胆固醇血症(HeFH)。剂量递增设计(0.1-0.6mg/kg)。初步结果：最高剂量组LDL胆固醇降低39-55%，PCSK9蛋白降低47-84%。安全性：一过性转氨酶升高(1-2级)，无严重不良事件。是首个体内碱基编辑人体试验。", "tags": ["VERVE-101", "clinical_trial", "base_editing", "PCSK9"], "difficulty": "medium", "question_type": "clinical", "source": "GEAlmanac", "required_modules": ["almanac", "retrieval"], "key_entities": ["VERVE-101", "PCSK9", "LDL", "HeFH", "ABE", "LNP"], "evidence_dois": ["10.1056/NEJMoa2303765"], "language": "zh"}
{"id": "CL02", "question": "NTLA-2001的给药方式、靶点和Phase I疗效数据", "answer": "NTLA-2001: LNP包裹Cas9 mRNA + TTR靶向sgRNA，单次静脉注射(0.1-0.3mg/kg)。Phase I(NCT04601051, NEJM 2021): 0.3mg/kg组血清TTR蛋白降低87%，6个月后维持。治疗遗传性ATTR淀粉样变性。安全性：轻度输液反应，无剂量限制性毒性。是首个证明体内CRISPR编辑临床可行性的试验。", "tags": ["NTLA-2001", "clinical_trial", "CRISPR-Cas9", "TTR"], "difficulty": "medium", "question_type": "clinical", "source": "GEAlmanac", "required_modules": ["almanac", "retrieval"], "key_entities": ["NTLA-2001", "TTR", "87%", "NEJM", "LNP"], "evidence_dois": ["10.1056/NEJMoa2107454"], "language": "zh"}
{"id": "CL03", "question": "Casgevy的完整治疗流程包括哪些步骤？", "answer": "1)动员+采集: G-CSF/Plerixafor动员HSC→白细胞采集术收集CD34+细胞; 2)编辑: 电穿孔RNP(Cas9蛋白+BCL11A增强子靶向sgRNA)至CD34+细胞; 3)预处理: 患者接受白消安清髓预处理(4天); 4)回输: 编辑后的HSC静脉回输至患者; 5)植入监测: 监测中性粒细胞和血小板恢复(通常2-6周); 6)HbF上升: 编辑细胞扩增后HbF逐步上升。", "tags": ["Casgevy", "clinical", "ex_vivo", "procedure"], "difficulty": "medium", "question_type": "clinical", "source": "GEAlmanac", "required_modules": ["almanac", "retrieval"], "key_entities": ["Casgevy", "CD34+", "白消安", "清髓", "HbF", "电穿孔"], "evidence_dois": [], "language": "zh"}
{"id": "CL04", "question": "CTX110通用型CAR-T的基因编辑策略和临床状态", "answer": "CTX110(CRISPR Therapeutics, NCT04438083): CRISPR编辑健康供者T细胞→敲除TRAC(消除GvHD)和B2M(逃避宿主NK杀伤)→整合CD19 CAR构建体。Phase I治疗r/r B-ALL/DLBCL。结果：客观缓解率67%，CR率37%。挑战：持久性不如自体CAR-T，可能需桥接移植。是首个同种异体CRISPR CAR-T临床试验之一。", "tags": ["CAR-T", "CRISPR", "allogeneic", "clinical_trial"], "difficulty": "medium", "question_type": "clinical", "source": "GEAlmanac", "required_modules": ["almanac", "retrieval"], "key_entities": ["CTX110", "TRAC", "B2M", "CD19", "CAR-T"], "evidence_dois": [], "language": "zh"}
{"id": "CL05", "question": "EDIT-101治疗LCA10的技术路线和临床进展", "answer": "EDIT-101(Editas Medicine, NCT03872479)：AAV5包裹SaCas9+双sgRNA，视网膜下注射。切除CEP290基因IVS26内含子中的隐蔽剪接位点突变(c.2991+1655A>G)→恢复正常CEP290剪接→恢复纤毛功能→改善视力。Phase I/II: 部分患者视功能改善，但效果变异大。是首个体内CRISPR编辑人体试验(2020年3月首例给药)。", "tags": ["EDIT-101", "LCA10", "CEP290", "AAV", "clinical_trial"], "difficulty": "medium", "question_type": "clinical", "source": "GEAlmanac", "required_modules": ["almanac", "retrieval"], "key_entities": ["EDIT-101", "CEP290", "LCA10", "SaCas9", "AAV5"], "evidence_dois": [], "language": "zh"}
{"id": "CL06", "question": "Intellia NTLA-3001靶向什么基因治疗什么疾病？", "answer": "NTLA-3001靶向KLKB1基因(编码激肽释放酶前体)，通过LNP递送CRISPR至肝脏敲除KLKB1→减少缓激肽(bradykinin)产生→治疗遗传性血管性水肿(HAE)。临床结果显示靶蛋白降低>90%，发作频率显著减少。是Intellia继NTLA-2001后第二个体内CRISPR疗法。", "tags": ["NTLA-3001", "KLKB1", "HAE", "clinical_trial"], "difficulty": "medium", "question_type": "clinical", "source": "GEAlmanac", "required_modules": ["almanac", "retrieval"], "key_entities": ["NTLA-3001", "KLKB1", "缓激肽", "HAE", "LNP"], "evidence_dois": [], "language": "zh"}
{"id": "CL07", "question": "PCSK9功能缺失突变人群为何成为基因编辑靶点验证的天然证据？", "answer": "流行病学研究发现PCSK9 LOF突变携带者(如Q152H, C679X)LDL降低28-40%，冠心病风险降低88%，且无明显不良表型——这属于罕见的'natural experiment'，证明了PCSK9完全敲除的长期安全性。加上PCSK9单抗(evolocumab/alirocumab)已证明LDL降低→心血管获益的因果关系，使PCSK9成为最robust的碱基编辑靶点之一。", "tags": ["PCSK9", "target_validation", "clinical"], "difficulty": "hard", "question_type": "clinical", "source": "literature", "required_modules": ["almanac", "retrieval"], "key_entities": ["PCSK9", "LOF", "LDL", "88%", "冠心病"], "evidence_dois": [], "language": "zh"}
{"id": "CL08", "question": "清髓预处理在ex vivo基因编辑治疗中的作用和风险", "answer": "作用: 白消安(busulfan)清除骨髓中原有HSC→腾出'壁龛(niche)'用于编辑后HSC植入→确保编辑细胞长期造血。风险: 骨髓抑制→严重感染(中性粒细胞低下2-4周)、出血(血小板低下)、VOD(静脉闭塞病)、不育(生殖毒性)、二次肿瘤风险。清髓是Casgevy治疗的最大安全担忧和患者负担。非清髓方案(如抗CD117单抗)正在研发中。", "tags": ["myeloablation", "ex_vivo", "safety", "clinical"], "difficulty": "medium", "question_type": "clinical", "source": "literature", "required_modules": ["retrieval", "safety_firewall"], "key_entities": ["白消安", "清髓", "HSC", "VOD", "niche"], "evidence_dois": [], "language": "zh"}
{"id": "CL09", "question": "Prime Medicine PM359是什么？为何具有里程碑意义？", "answer": "PM359是Prime Medicine开发的首个Prime Editing IND(Investigational New Drug)，靶向CDKL5缺陷(一种严重癫痫性脑病)，NCT06245005。里程碑意义：1)首个进入临床的prime editing疗法; 2)证明PE可以从实验室走向临床; 3)为PE在无法用BE处理的突变类型中开辟了治疗路径。预计2024年底开始Phase I给药。", "tags": ["PM359", "prime_editing", "clinical_trial", "CDKL5"], "difficulty": "medium", "question_type": "clinical", "source": "GEAlmanac", "required_modules": ["almanac", "retrieval"], "key_entities": ["PM359", "CDKL5", "Prime Editing", "IND"], "evidence_dois": [], "language": "zh"}
{"id": "CL10", "question": "WVE-006 RNA编辑疗法的靶点、机制和临床意义", "answer": "WVE-006(Wave Life Sciences): 立体纯化反义寡核苷酸(stereopure ASO)，招募内源ADAR酶→编辑SERPINA1 mRNA中的Z突变(E342K)→A-to-I编辑恢复正常M-AAT蛋白。治疗α1-抗胰蛋白酶缺乏症(AATD)。临床意义：不需递送外源编辑蛋白(仅ASO)，可重复给药，是RNA编辑内源ADAR策略的临床验证。", "tags": ["WVE-006", "RNA_editing", "ADAR", "clinical_trial"], "difficulty": "medium", "question_type": "clinical", "source": "GEAlmanac", "required_modules": ["almanac", "retrieval"], "key_entities": ["WVE-006", "SERPINA1", "ADAR", "AATD", "ASO"], "evidence_dois": [], "language": "zh"}
{"id": "CL11", "question": "CRISPR在DMD(杜氏肌营养不良)治疗中的外显子跳跃策略", "answer": "DMD通常由dystrophin基因外显子缺失导致移码→无功能蛋白。CRISPR外显子跳跃：用双sgRNA删除突变外显子两侧的剪接位点→外显子被跳过→恢复阅读框→产生截短但部分功能的dystrophin(类似较轻的Becker型)。最常跳跃exon 51(~13% DMD患者适用)。挑战：需全身高剂量AAV递送至肌肉，免疫原性和肝毒性是主要风险。", "tags": ["DMD", "exon_skipping", "CRISPR", "clinical"], "difficulty": "hard", "question_type": "clinical", "source": "literature", "required_modules": ["retrieval", "variant_resolver"], "key_entities": ["DMD", "dystrophin", "外显子跳跃", "exon 51", "AAV"], "evidence_dois": [], "language": "zh"}
{"id": "CL12", "question": "目前体内碱基编辑的首个人体临床试验是哪个？结果如何？", "answer": "VERVE-101(Verve Therapeutics, NCT05398029)是首个体内碱基编辑人体临床试验，2022年启动。使用ABE8e通过LNP静脉注射靶向肝脏PCSK9基因。Phase Ib中期数据：最高剂量组(0.6mg/kg)LDL-C降低55%，PCSK9蛋白降低84%。安全性良好，仅一过性1-2级转氨酶升高。", "tags": ["VERVE-101", "base_editing", "first_in_human", "clinical"], "difficulty": "easy", "question_type": "clinical", "source": "GEAlmanac", "required_modules": ["almanac"], "key_entities": ["VERVE-101", "首个", "体内碱基编辑", "PCSK9"], "evidence_dois": [], "language": "zh"}
{"id": "CL13", "question": "CAR-T治疗中TRAC基因敲除的目的是什么？", "answer": "TRAC(T Cell Receptor Alpha Constant)编码TCR α链。敲除TRAC→T细胞丧失内源TCR表达→消除同种异体T细胞识别宿主抗原引起的移植物抗宿主病(GvHD)。这使得可以使用健康供者T细胞制备'通用型'(off-the-shelf) CAR-T，不需要为每个患者定制，大幅降低成本和等待时间。", "tags": ["CAR-T", "TRAC", "GvHD", "clinical"], "difficulty": "easy", "question_type": "clinical", "source": "literature", "required_modules": ["retrieval", "almanac"], "key_entities": ["TRAC", "TCR", "GvHD", "通用型CAR-T"], "evidence_dois": [], "language": "zh"}
{"id": "CL14", "question": "基因编辑治疗的费用如何与终身药物治疗比较？", "answer": "以SCD为例：Casgevy $220万/次(一次性) vs 终身输血+螯合+VOC管理 约$400万-$600万/生命周期。以HeFH为例：VERVE-101(预估$20-50万/次一次性) vs PCSK9单抗 $425/月×生命周期 约$200万+。基因编辑在慢性病管理中理论上具有药物经济学优势，但一次性大额支付对医保系统挑战巨大。", "tags": ["cost", "health_economics", "clinical"], "difficulty": "medium", "question_type": "clinical", "source": "expert_knowledge", "required_modules": ["almanac", "retrieval"], "key_entities": ["220万", "一次性", "终身", "药物经济学"], "evidence_dois": [], "language": "zh"}
{"id": "CL15", "question": "What clinical trials are evaluating CRISPR for HIV treatment?", "answer": "Key trials: 1) EBT-101 (Excision Bio, NCT05144386): AAV9 delivers dual Cas9 to excise integrated HIV proviral DNA from reservoir cells in ART-suppressed patients; 2) XBP-CSR01: CRISPR-edited CD4+ T cells with disrupted CCR5 (mimicking Δ32 natural resistance); 3) CRISPR KO of CCR5 in HSCs followed by transplant. Challenges: reaching latent reservoir (only 1 in 10^6 cells), multi-tissue delivery, and preventing viral rebound.", "tags": ["HIV", "CRISPR", "clinical_trial"], "difficulty": "medium", "question_type": "clinical", "source": "literature", "required_modules": ["retrieval", "almanac"], "key_entities": ["EBT-101", "CCR5", "HIV", "proviral", "reservoir"], "evidence_dois": [], "language": "en"}
{"id": "CL16", "question": "自体(autologous)和异体(allogeneic)细胞治疗产品的监管差异", "answer": "自体产品(如Casgevy): 为每位患者个体化制备→按个体化疗法监管→CMC(化学制造控制)更灵活但需证明一致性; 异体产品(如CTX110): 从一个供者批量制备→更接近传统药物监管→需要更严格的标准化和批次一致性证明。异体产品还需额外评估GvHD风险和免疫排斥，监管审查更复杂但商业化潜力更大。", "tags": ["regulatory", "autologous", "allogeneic", "clinical"], "difficulty": "hard", "question_type": "clinical", "source": "expert_knowledge", "required_modules": ["retrieval"], "key_entities": ["自体", "异体", "CMC", "GvHD", "监管"], "evidence_dois": [], "language": "zh"}
{"id": "CL17", "question": "AAV基因治疗中出现过哪些严重不良事件？", "answer": "重要安全事件: 1) Zolgensma(AAV9, SMA): 高剂量引起急性肝衰竭→多例死亡报告; 2) AT132(Audentes/Astellas): XLMTM治疗中3名患者因进行性肝功能衰竭死亡(高剂量AAV8); 3) ASPIRO试验: 肝毒性+胆汁淤积; 4) James Wilson实验室: 高剂量AAV至NHP后背根神经节(DRG)毒性。教训：AAV高剂量系统给药的肝毒性是主要风险，推动了向LNP等非病毒载体的转变。", "tags": ["AAV", "safety", "adverse_events", "clinical"], "difficulty": "medium", "question_type": "clinical", "source": "literature", "required_modules": ["retrieval", "failure_case_db"], "key_entities": ["Zolgensma", "AT132", "肝毒性", "死亡", "DRG毒性"], "evidence_dois": [], "language": "zh"}
{"id": "CL18", "question": "EMA和FDA对基因编辑疗法的审批路径有何差异？", "answer": "FDA: BLA(Biologics License Application)路径，可获Orphan Drug Designation(7年独占)、Breakthrough Therapy(加速审评)、RMAT(再生医学高级疗法)。EMA: ATMP(Advanced Therapy Medicinal Product)分类，通过CAT(细胞治疗高级委员会)评估后由CHMP审批，MAA(Marketing Authorization Application)。差异：FDA单臂试验可获加速批准，EMA通常要求更多比较数据；FDA附条件批准更灵活。", "tags": ["FDA", "EMA", "regulatory", "clinical"], "difficulty": "hard", "question_type": "clinical", "source": "expert_knowledge", "required_modules": ["retrieval"], "key_entities": ["FDA", "EMA", "BLA", "ATMP", "加速审评"], "evidence_dois": [], "language": "zh"}
{"id": "CL19", "question": "基因编辑临床试验中的剂量递增设计原则", "answer": "典型设计：1)3+3设计或加速滴定(accelerated titration)→确定MTD; 2)基因编辑特殊性:不同于小分子可排泄，编辑效果永久→需更保守的起始剂量(通常从最低预期药效学剂量的1/10开始); 3)LNP体内编辑以mg/kg计(如NTLA-2001: 0.1→0.3mg/kg); 4)需设定DLT窗口期(通常28天，但编辑疗法可能需要更长监测期); 5)中间分析包含编辑效率评估(biallelic vs monoallelic editing比例)。", "tags": ["clinical_trial", "dose_escalation", "design"], "difficulty": "hard", "question_type": "clinical", "source": "expert_knowledge", "required_modules": ["retrieval"], "key_entities": ["3+3设计", "MTD", "DLT", "mg/kg", "剂量递增"], "evidence_dois": [], "language": "zh"}
{"id": "CL20", "question": "CRISPR在治疗β-地中海贫血中有哪些不同的技术路线？", "answer": "路线1(已获批): BCL11A增强子KO→重激活HbF(Casgevy); 路线2: HBG启动子编辑→引入HPFH样突变(CBE,临床前); 路线3: 直接纠正HBB突变→特定突变适用(如IVS-I-110用ABE,临床前); 路线4: β-globin基因敲入→CRISPR HDR在AAVS1安全港位点(早期研发)。路线选择取决于突变类型(β0 vs β+)和临床成熟度。", "tags": ["thalassemia", "treatment_routes", "clinical"], "difficulty": "hard", "question_type": "clinical", "source": "expert_knowledge", "required_modules": ["almanac", "variant_resolver", "retrieval"], "key_entities": ["BCL11A", "HBG", "HBB", "HPFH", "IVS-I-110"], "evidence_dois": [], "language": "zh"}
{"id": "S01", "question": "CRISPR-Cas9产生的DSB可能导致哪些基因组安全风险？", "answer": "主要风险: 1)大片段缺失(kb级,频率1-20%); 2)染色体易位(多位点编辑时); 3)chromothripsis(染色体碎裂,罕见但灾难性); 4)p53通路激活→选择p53缺陷细胞(潜在致癌风险); 5)微核形成; 6)LOH(杂合性丢失)。缓解策略：使用无DSB编辑器(BE/PE)、短暂递送(RNP/mRNA)、单细胞测序质控。", "tags": ["safety", "DSB", "genotoxicity"], "difficulty": "hard", "question_type": "safety", "source": "literature", "required_modules": ["safety_firewall", "retrieval"], "key_entities": ["DSB", "大片段缺失", "chromothripsis", "p53", "LOH"], "evidence_dois": [], "language": "zh"}
{"id": "S02", "question": "碱基编辑器的旁观者编辑(bystander editing)风险是什么？如何缓解？", "answer": "旁观者编辑指编辑窗口内非靶标碱基也被脱氨修改。例如ABE窗口4-8内有多个A时，目标A和旁观者A都可能被编辑→产生非预期氨基酸变化。缓解：1)选择窗口内仅含单一靶碱基的位点; 2)使用窗口更窄的变体(如ABE8e窗口4-7); 3)改用Prime Editing(精确到单碱基)。", "tags": ["base_editing", "bystander", "safety"], "difficulty": "medium", "question_type": "safety", "source": "literature", "required_modules": ["safety_firewall", "variant_resolver", "retrieval"], "key_entities": ["旁观者编辑", "编辑窗口", "ABE8e", "Prime Editing"], "evidence_dois": [], "language": "zh"}
{"id": "S03", "question": "Cas9持续表达为何增加脱靶风险？如何降低？", "answer": "Cas9持续表达(如AAV长期转导)使Cas9蛋白在细胞内累积→更多时间扫描基因组→低亲和力脱靶位点也有概率被切割→脱靶累积。降低策略：1)瞬时递送(RNP半衰期<24h, mRNA半衰期12-24h); 2)self-limiting设计(sgRNA靶向Cas9表达盒); 3)anti-CRISPR蛋白时序控制; 4)小分子可调控Cas9(ligand-dependent)。", "tags": ["off_target", "Cas9", "safety"], "difficulty": "medium", "question_type": "safety", "source": "literature", "required_modules": ["safety_firewall", "retrieval"], "key_entities": ["持续表达", "脱靶累积", "RNP", "瞬时递送", "anti-CRISPR"], "evidence_dois": [], "language": "zh"}
{"id": "S04", "question": "p53通路在CRISPR编辑中的安全性意义", "answer": "Haapaniemi 2018 Nature Medicine报道：Cas9产生DSB激活p53-p21 DDR通路→引起细胞周期阻滞/凋亡→p53功能正常的细胞被选择性清除→编辑效率偏低的细胞恰恰是p53正常细胞。隐患：长期培养中可能富集p53缺陷细胞→增加致癌风险。缓解：1)短暂编辑窗口; 2)编辑后TP53突变筛查; 3)使用无DSB编辑器。", "tags": ["p53", "safety", "selection"], "difficulty": "hard", "question_type": "safety", "source": "literature", "required_modules": ["safety_firewall", "retrieval"], "key_entities": ["p53", "DDR", "选择性富集", "TP53", "致癌"], "evidence_dois": [], "language": "zh"}
{"id": "S05", "question": "基因编辑临床试验中有哪些必须进行的安全性检测？", "answer": "必要安全检测：1)脱靶分析: GUIDE-seq/CIRCLE-seq+全基因组测序验证top脱靶; 2)核型分析: 检测大片段缺失和染色体异常; 3)易位检测: CAST-seq或HTGTS; 4)生物分布: 编辑器在非靶组织的活性; 5)免疫原性: 抗Cas9/AAV抗体; 6)致瘤性: 长期动物模型肿瘤监测; 7)编辑效率定量: on-target biallelic/monoallelic比例。", "tags": ["safety", "clinical_trial", "assays"], "difficulty": "hard", "question_type": "safety", "source": "expert_knowledge", "required_modules": ["safety_firewall", "retrieval"], "key_entities": ["GUIDE-seq", "核型", "易位", "生物分布", "致瘤性"], "evidence_dois": [], "language": "zh"}
{"id": "S06", "question": "LNP递送的主要免疫反应和毒性风险", "answer": "1)急性注射反应: 补体激活(CARPA)→过敏样症状; 2)PEG抗体: 反复给药产生抗PEG IgM→加速血液清除(ABC现象); 3)肝毒性: 转氨酶一过性升高(1-3级,NTLA-2001和VERVE-101均观察到); 4)炎症因子: IL-6等细胞因子释放; 5)脾脏毒性: LNP部分积累于脾脏。当前缓解：慢速输注、预处理(地塞米松+抗组胺)、优化PEG脂质。", "tags": ["LNP", "toxicity", "safety"], "difficulty": "medium", "question_type": "safety", "source": "literature", "required_modules": ["safety_firewall", "delivery_tree", "retrieval"], "key_entities": ["CARPA", "PEG", "转氨酶", "ABC现象", "IL-6"], "evidence_dois": [], "language": "zh"}
{"id": "S07", "question": "生殖系基因编辑的主要伦理争议和国际共识", "answer": "争议：1)不可逆遗传改变传递给后代; 2)无法获得未出生者知情同意; 3)滑坡效应→Enhancement/设计婴儿; 4)技术不成熟(脱靶嵌合体风险); 5)社会公平性。国际共识(2023 London Summit+WHO 2021)：体细胞基因治疗可在监管下推进；生殖系编辑的临床应用应暂停(moratorium)直至安全和伦理标准成熟；基础研究在伦理审查下可进行。", "tags": ["ethics", "germline", "safety"], "difficulty": "hard", "question_type": "safety", "source": "expert_knowledge", "required_modules": ["safety_firewall", "retrieval"], "key_entities": ["生殖系", "知情同意", "moratorium", "WHO", "伦理"], "evidence_dois": [], "language": "zh"}
{"id": "S08", "question": "碱基编辑器的RNA水平脱靶是如何产生的？有何后果？", "answer": "CBE中的APOBEC和ABE中的TadA脱氨酶可脱离sgRNA引导，直接作用于胞质中的mRNA/rRNA，产生全转录组范围的脱靶编辑。CBE RNA脱靶率较高(C-to-U 0.1-1%), ABE较低但ABE8e有所增加。后果：大多数RNA脱靶因mRNA turnover而短暂，但可能产生错误蛋白。缓解：ABE8e-V106W变体显著降低RNA脱靶; CBE使用YE1等窗口缩窄变体。", "tags": ["base_editing", "RNA_off_target", "safety"], "difficulty": "hard", "question_type": "safety", "source": "literature", "required_modules": ["safety_firewall", "retrieval"], "key_entities": ["RNA脱靶", "APOBEC", "TadA", "V106W", "YE1"], "evidence_dois": [], "language": "zh"}
{"id": "S09", "question": "嵌合体(mosaicism)在基因编辑中的安全意义", "answer": "嵌合体指同一组织中存在不同编辑状态的细胞(编辑/未编辑/不同编辑产物)。安全意义：1)治疗效果不均一(部分细胞未被纠正); 2)有害编辑产物无法被完全清除; 3)体内编辑难以避免(不同细胞接收不同剂量)。特别在生殖系编辑中，嵌合体意味着不可预测的遗传后果。检测：单细胞测序、数字PCR定量allele频率。", "tags": ["mosaicism", "safety"], "difficulty": "hard", "question_type": "safety", "source": "literature", "required_modules": ["safety_firewall", "retrieval"], "key_entities": ["嵌合体", "单细胞测序", "allele频率", "生殖系"], "evidence_dois": [], "language": "zh"}
{"id": "S10", "question": "How does CRISPR editing potentially activate innate immune responses?", "answer": "1) dsDNA from Cas9 cutting activates cGAS-STING pathway→type I IFN; 2) In vitro transcribed sgRNA can trigger TLR3/7/8/RIG-I if not properly modified (2'-OMe/phosphorothioate); 3) Cas9 protein (bacterial origin) triggers adaptive immune response in ~50% of humans with pre-existing T cells; 4) AAV capsid activates TLR9 via CpG motifs; 5) LNP components activate complement. Mitigation: chemical modification of guides, transient delivery, immunosuppression pre-treatment.", "tags": ["innate_immunity", "safety"], "difficulty": "hard", "question_type": "safety", "source": "literature", "required_modules": ["safety_firewall", "retrieval"], "key_entities": ["cGAS-STING", "TLR", "Cas9 immunity", "complement"], "evidence_dois": [], "language": "en"}
{"id": "S11", "question": "基因编辑后大片段缺失的检测方法有哪些？", "answer": "1)长读长测序(PacBio/ONT): 直接检测kb级缺失; 2)ddPCR(微滴数字PCR): 用跨越编辑位点的引物定量完整vs缺失allele; 3)CAST-seq: 检测DSB诱导的易位; 4)UniDirectional TOPO-seq: 捕获单向大片段缺失; 5)核型分析/FISH: 检测染色体水平变化。短读长NGS容易漏检大片段缺失(mapping bias)。FDA指南建议组合使用多种方法。", "tags": ["large_deletion", "detection", "safety"], "difficulty": "hard", "question_type": "safety", "source": "literature", "required_modules": ["safety_firewall", "retrieval"], "key_entities": ["长读长测序", "ddPCR", "CAST-seq", "大片段缺失", "FDA"], "evidence_dois": [], "language": "zh"}
{"id": "S12", "question": "He Jiankui事件的科学和伦理问题总结", "answer": "2018年He Jiankui宣布使用CRISPR编辑CCR5基因创造首例基因编辑婴儿(Lulu和Nana)。科学问题：1)CCR5Δ32并非完全保护HIV; 2)编辑产生嵌合体; 3)未充分进行脱靶分析; 4)未达到双allele纯合编辑。伦理问题：1)未获适当伦理批准; 2)知情同意有缺陷; 3)无医学必要性(父亲HIV可通过精子洗涤处理); 4)秘密进行。后果：入狱3年，全球暂停生殖系编辑临床。", "tags": ["ethics", "He_Jiankui", "germline", "safety"], "difficulty": "medium", "question_type": "safety", "source": "expert_knowledge", "required_modules": ["safety_firewall", "retrieval"], "key_entities": ["He Jiankui", "CCR5", "嵌合体", "伦理", "生殖系"], "evidence_dois": [], "language": "zh"}
{"id": "S13", "question": "Cas9蛋白预存免疫反应的临床意义", "answer": "约50-70%人群因暴露于链球菌/葡萄球菌而拥有抗SpCas9/SaCas9的预存T细胞和抗体。临床意义：1)体内递送后Cas9表达细胞可能被CTL清除→降低编辑效率; 2)抗体可中和Cas9; 3)可能引起免疫介导的组织损伤。缓解：瞬时递送(RNP/mRNA表达窗口短)、免疫抑制预处理、使用非人源Cas变体(如来自古菌的CasMINI)。", "tags": ["Cas9", "immunity", "safety"], "difficulty": "medium", "question_type": "safety", "source": "literature", "required_modules": ["safety_firewall", "retrieval"], "key_entities": ["预存免疫", "CTL", "抗体", "RNP", "免疫原性"], "evidence_dois": [], "language": "zh"}
{"id": "SD01", "question": "如何为一个特定点突变疾病设计最优的基因编辑治疗策略？", "answer": "决策流程：1)确定突变类型(ClinVar): 错义→碱基编辑(若可匹配A→G或C→T); 无义→read-through或基因补充; 移码→外显子跳跃或Prime Edit; 2)检查PAM可及性: 靶碱基在BE窗口4-8内且附近有NGG; 3)评估递送路线: 靶组织→肝脏(LNP)、血液(ex vivo RNP)、眼(AAV局部); 4)安全性评估: GUIDE-seq脱靶谱、旁观者编辑; 5)参考已有临床先例: 优先选择有先例的技术路线。", "tags": ["strategy", "decision_making", "treatment_design"], "difficulty": "hard", "question_type": "strategy_design", "source": "expert_knowledge", "required_modules": ["variant_resolver", "delivery_tree", "almanac", "retrieval"], "key_entities": ["点突变", "碱基编辑", "PAM", "递送", "决策流程"], "evidence_dois": [], "language": "zh"}
{"id": "SD02", "question": "设计一个针对肝脏靶向基因编辑的最优递送方案", "answer": "推荐: LNP-mRNA递送方案。设计要素：1)LNP组成: MC3类可电离脂质(pKa~6.4)+DSPC+Chol+PEG-DMG(比例50:10:38.5:1.5 mol%); 2)载荷: Cas9/BE mRNA(N1-methylpseudouridine修饰)+sgRNA(化学修饰2'-OMe+PS); 3)给药: 0.1-0.3mg/kg IV; 4)预处理: 地塞米松+抗组胺药; 5)ApoE吸附→LDL受体介导肝细胞摄取。优势: 可重复给药、瞬时表达安全性好。参考: NTLA-2001, VERVE-101均验证此路线。", "tags": ["liver", "LNP", "delivery", "strategy_design"], "difficulty": "hard", "question_type": "strategy_design", "source": "expert_knowledge", "required_modules": ["delivery_tree", "retrieval"], "key_entities": ["LNP", "MC3", "mRNA", "肝脏", "0.3mg/kg"], "evidence_dois": [], "language": "zh"}
{"id": "SD03", "question": "如何设计一个高效低脱靶的sgRNA？列出完整的设计流程", "answer": "流程: 1)确定靶区域和PAM分布(CRISPick/CHOPCHOP); 2)初筛: Rule Set 2得分>0.6、GC含量40-70%、无poly-T(>4T); 3)脱靶预测: Cas-OFFinder全基因组搜索、CFD score>0.9; 4)避开外显子区脱靶(基因间区可容忍); 5)二级结构检查: 避免sgRNA自身折叠影响Cas9结合; 6)seed区(PAM近端12nt)与top脱靶位点比对; 7)化学修饰: 前3后3个碱基2'-OMe+PS修饰提高稳定性; 8)实验验证: T7E1/NGS测定编辑效率和脱靶谱。", "tags": ["sgRNA", "design", "strategy"], "difficulty": "hard", "question_type": "strategy_design", "source": "expert_knowledge", "required_modules": ["sequence_context", "retrieval"], "key_entities": ["sgRNA设计", "CRISPick", "CFD", "seed区", "化学修饰"], "evidence_dois": [], "language": "zh"}
{"id": "SD04", "question": "为DMD外显子51跳跃设计完整的CRISPR治疗方案", "answer": "方案: 1)编辑策略: 双sgRNA删除exon 51两侧剪接位点→外显子跳跃→恢复阅读框→产生Becker型dystrophin(~13% DMD患者适用); 2)编辑器: SaCas9(更小,适合AAV); 3)递送: 双AAV方案(AAV9全身IV高剂量)→跨越BBB且肌肉嗜性; 4)剂量: 1-2×10^14 vg/kg(参考Zolgensma); 5)安全性: 预存AAV9抗体筛查、肝功能监测、免疫抑制预处理; 6)终点: dystrophin Western blot(>10%正常水平)、6分钟步行距离。", "tags": ["DMD", "exon_skipping", "strategy_design"], "difficulty": "hard", "question_type": "strategy_design", "source": "expert_knowledge", "required_modules": ["variant_resolver", "delivery_tree", "retrieval"], "key_entities": ["DMD", "exon 51", "SaCas9", "AAV9", "dystrophin"], "evidence_dois": [], "language": "zh"}
{"id": "SD05", "question": "设计一个通用型(off-the-shelf)CAR-T产品的基因编辑方案", "answer": "方案: 1)供者: 健康供者PBMC→T细胞活化扩增; 2)编辑: 多重Cas9 RNP电穿孔→同时敲除TRAC(防GvHD)+B2M(逃避NK)+PD-1(增强抗肿瘤); 3)CAR整合: 慢病毒转导CD19-4-1BB-CD3ζ CAR或CRISPR HDR敲入TRAC位点; 4)质控: 残留TCR表达<0.5%(流式)、CAR+比例>70%、核型正常; 5)冷冻保存: 批量制备→分装冻存→按需解冻; 6)给药: 淋巴清除预处理(Flu/Cy)+CAR-T输注。", "tags": ["CAR-T", "allogeneic", "strategy_design"], "difficulty": "hard", "question_type": "strategy_design", "source": "expert_knowledge", "required_modules": ["almanac", "retrieval"], "key_entities": ["CAR-T", "TRAC", "B2M", "PD-1", "通用型"], "evidence_dois": [], "language": "zh"}
{"id": "SD06", "question": "如何建立基因编辑产品的全面安全性评估体系？", "answer": "体系: 1)计算预测: Cas-OFFinder脱靶位点预测+脱靶评分; 2)体外验证: GUIDE-seq(金标准)+CIRCLE-seq(高灵敏度); 3)基因组完整性: 长读长WGS(缺失)、核型(大结构变异)、CAST-seq(易位); 4)功能安全: p53通路完整性(TP53 NGS)、致瘤性(软琼脂集落+裸鼠); 5)免疫安全: Cas9预存免疫血清学、CRS标志物; 6)长期监测: 15年随访(FDA RMAT要求)、插入位点分析(LSM-PCR if applicable)。", "tags": ["safety", "assessment", "strategy_design"], "difficulty": "hard", "question_type": "strategy_design", "source": "expert_knowledge", "required_modules": ["safety_firewall", "retrieval"], "key_entities": ["安全性评估", "GUIDE-seq", "WGS", "p53", "15年随访"], "evidence_dois": [], "language": "zh"}
{"id": "SD07", "question": "Design an optimal base editing strategy for treating heterozygous familial hypercholesterolemia", "answer": "Strategy: 1) Target: PCSK9 splice site (exon 1 donor) or W159X premature stop codon introduction via CBE; 2) Editor: ABE8e targeting splice donor AG→GG (VERVE-101 approach) for highest efficiency; 3) Delivery: LNP-mRNA IV (liver tropism), 0.3-0.6 mg/kg; 4) Expected outcome: >50% PCSK9 reduction → 40-55% LDL decrease; 5) Safety: monitor transaminases, lipid panel, off-target liver biopsy NGS; 6) Advantage over statins/PCSK9-mAb: one-time curative vs lifelong treatment.", "tags": ["base_editing", "PCSK9", "HeFH", "strategy_design"], "difficulty": "hard", "question_type": "strategy_design", "source": "expert_knowledge", "required_modules": ["variant_resolver", "delivery_tree", "almanac", "retrieval"], "key_entities": ["ABE8e", "PCSK9", "LNP", "HeFH", "splice site"], "evidence_dois": [], "language": "en"}
{"id": "SD08", "question": "如何评估一个新型基因编辑器的临床转化潜力？", "answer": "评估框架: 1)编辑效率: 在治疗相关细胞类型中>30%(HSC/T-cell/hepatocyte); 2)特异性: 全基因组脱靶分析，off:on ratio<1%; 3)可递送性: 蛋白大小(单AAV<4.7kb)或mRNA/RNP兼容性; 4)产物纯度: indel谱分析(frameshift vs in-frame比例可预测); 5)专利状况: FTO(freedom to operate)分析; 6)CMC可行性: GMP级生产可行; 7)临床先例: 同类编辑器已有IND更优; 8)安全性profile: 无p53选择、无染色体异常。", "tags": ["translational", "assessment", "strategy_design"], "difficulty": "hard", "question_type": "strategy_design", "source": "expert_knowledge", "required_modules": ["patent", "retrieval"], "key_entities": ["临床转化", "编辑效率", "可递送性", "FTO", "GMP"], "evidence_dois": [], "language": "zh"}
{"id": "MH01", "question": "从PCSK9功能缺失的人群遗传学证据到VERVE-101临床试验，请梳理完整的转化医学路径", "answer": "路径: 1)人群遗传学: PCSK9 LOF携带者LDL↓28-40%、冠心病↓88%→靶点验证; 2)单抗验证: evolocumab/alirocumab证明PCSK9抑制→LDL↓→心血管获益(FOURIER trial); 3)工具开发: ABE8e碱基编辑器→高效A→G(Richter 2020); 4)递送技术: LNP→肝脏(Alnylam patisiran先例); 5)动物POC: NHP中ABE+LNP→PCSK9↓60%+维持>1年(Musunuru 2021 Nature); 6)临床转化: VERVE-101 Phase Ib→LDL↓55%; 7)一次性治疗vs终身注射→药物经济学优势。", "tags": ["PCSK9", "translational", "multi_hop"], "difficulty": "hard", "question_type": "multi_hop", "source": "expert_knowledge", "required_modules": ["almanac", "retrieval", "cross_species"], "key_entities": ["PCSK9", "LOF", "ABE8e", "LNP", "NHP", "VERVE-101"], "evidence_dois": [], "language": "zh"}
{"id": "MH02", "question": "解释为什么碱基编辑比HDR更适合治疗镰刀细胞病，并追溯技术演进路径", "answer": "推理链: 1)SCD突变: HBB E6V (GAG→GTG)→需要T→C回复; 2)ABE可实现T·A→C·G(互补链A→G); 3)HDR需DSB+供体模板，但HSC中HDR效率仅<10%(非分裂HSC中更低); 4)ABE无DSB→无chromothripsis/大片段缺失/p53选择; 5)ABE在CD34+ HSC中效率58-68%(Newby 2021 Nature); 6)技术演进: ABE7.10(2017,效率低)→ABE8e(2020,590x↑)→ABE8e-RNP针对HSC优化→当前临床前最佳数据; 7)NHEJ竞争问题在ABE中不存在(无DSB)。", "tags": ["base_editing", "SCD", "HDR", "multi_hop"], "difficulty": "hard", "question_type": "multi_hop", "source": "literature", "required_modules": ["variant_resolver", "almanac", "retrieval"], "key_entities": ["SCD", "HBB", "E6V", "ABE", "HDR", "CD34+"], "evidence_dois": [], "language": "zh"}
{"id": "MH03", "question": "从LNP天然肝脏嗜性的分子机制到首个体内CRISPR疗法获得临床验证，请串联关键知识", "answer": "知识链: 1)分子机制: LNP在血液中吸附ApoE→ApoE结合肝细胞LDL受体(LDLR)→受体介导内吞→内体酸化→可电离脂质质子化→内体逃逸→mRNA释放; 2)先例验证: Alnylam的patisiran(siRNA LNP)2018年FDA获批→验证LNP肝脏递送安全有效; 3)CRISPR应用: Intellia将Cas9 mRNA+sgRNA包入LNP→NTLA-2001; 4)临床验证: Phase I单次0.3mg/kg→TTR蛋白↓87%(NEJM 2021); 5)平台拓展: 同平台→NTLA-3001(KLKB1), VERVE-101(PCSK9)。", "tags": ["LNP", "liver", "NTLA-2001", "multi_hop"], "difficulty": "hard", "question_type": "multi_hop", "source": "literature", "required_modules": ["delivery_tree", "almanac", "retrieval"], "key_entities": ["ApoE", "LDLR", "patisiran", "NTLA-2001", "TTR"], "evidence_dois": ["10.1056/NEJMoa2107454"], "language": "zh"}
{"id": "MH04", "question": "CRISPR安全性问题如何推动了碱基编辑和先导编辑的发展？", "answer": "演进逻辑: 1)CRISPR-Cas9: DSB引发NHEJ→不可控indel+大片段缺失(2017年报道)+chromothripsis(Leibowitz 2021)+p53选择(Haapaniemi 2018); 2)碱基编辑(2016 David Liu): nCas9(仅切一条链)+脱氨酶→无DSB→消除大片段缺失和chromothripsis(但限于4种转换); 3)先导编辑(2019 David Liu): nCas9+RT→无DSB无脱氨酶→脱靶更低+可做所有12种替换+小indel→最精确但效率待提高; 4)下一代: PE5max+epegRNA接近碱基编辑效率; 5)RNA编辑: 从DNA到RNA→完全不碰基因组→终极安全性。", "tags": ["safety", "evolution", "multi_hop"], "difficulty": "hard", "question_type": "multi_hop", "source": "literature", "required_modules": ["safety_firewall", "almanac", "retrieval"], "key_entities": ["DSB", "碱基编辑", "先导编辑", "RNA编辑", "David Liu"], "evidence_dois": [], "language": "zh"}
{"id": "MH05", "question": "追溯AAV肝毒性事件如何改变了基因治疗递送格局", "answer": "事件链: 1)Zolgensma(AAV9,2019获批): 高剂量3×10^14vg/kg→急性肝衰竭→多例死亡; 2)AT132(AAV8): XLMTM试验3名患者肝衰竭死亡(2020); 3)FDA介入: 要求所有高剂量AAV试验加强肝功能监测; 4)行业反应: AAV剂量天花板限制了大分子编辑器(BE/PE)递送; 5)替代方案崛起: LNP-mRNA路线(瞬时表达+可重复+无基因组整合)→Intellia NTLA-2001成功→LNP成为体内编辑首选; 6)趋势: 2024-2025年新IND中LNP占比超过AAV。", "tags": ["AAV", "toxicity", "LNP", "multi_hop"], "difficulty": "hard", "question_type": "multi_hop", "source": "literature", "required_modules": ["failure_case_db", "delivery_tree", "retrieval"], "key_entities": ["Zolgensma", "AT132", "肝毒性", "LNP", "NTLA-2001"], "evidence_dois": [], "language": "zh"}
{"id": "MH06", "question": "从小鼠到人类的基因编辑效率转化差异及其原因", "answer": "转化链: 1)小鼠肝脏编辑: LNP-ABE在小鼠中可达>80%编辑效率; 2)NHP转化: 同类方案在NHP中效率降至40-60%(LNP剂量相同); 3)人类临床: VERVE-101 PCSK9编辑效率推算~30-50%; 4)差异原因: 体重差异(LNP剂量/kg→总量差异巨大)、肝脏血流量比例不同、LDLR表达密度差异、免疫清除(人有预存抗体)、种属特异性编辑位点差异; 5)启示: 小鼠→NHP转化率约0.5-0.7x, NHP→人约0.7-0.9x, 需要安全裕度。", "tags": ["translation", "mouse", "NHP", "human", "multi_hop"], "difficulty": "hard", "question_type": "multi_hop", "source": "expert_knowledge", "required_modules": ["cross_species", "retrieval"], "key_entities": ["小鼠", "NHP", "人类", "转化率", "LNP"], "evidence_dois": [], "language": "zh"}
{"id": "MH07", "question": "PCSK9靶向碱基编辑如何整合人群遗传学、NHP动物模型和临床试验三级证据？", "answer": "三级证据整合: L1人群遗传学: PCSK9 LOF突变(Q152H/C679X)→LDL↓28-40%、CHD↓88%→长期安全性已被自然验证+PCSK9单抗因果证据; L2 NHP模型: Musunuru 2021在食蟹猴中ABE+LNP单次注射→PCSK9↓60%+LDL↓60%→维持>8个月→无严重不良事件→支持human FIH; L3 临床试验: VERVE-101 Phase Ib→PCSK9↓84%+LDL↓55%→安全性良好→一过性转氨酶升高自行恢复。三级证据形成完整的target validation→POC→clinical translation链条。", "tags": ["PCSK9", "evidence_hierarchy", "multi_hop"], "difficulty": "hard", "question_type": "multi_hop", "source": "expert_knowledge", "required_modules": ["almanac", "cross_species", "retrieval"], "key_entities": ["PCSK9", "LOF", "NHP", "VERVE-101", "三级证据"], "evidence_dois": [], "language": "zh"}
{"id": "MH08", "question": "从ADAR的天然生物学到RNA编辑治疗, 追溯从基础研究到WVE-006临床试验的路径", "answer": "路径: 1)基础: ADAR1/2在生理条件下编辑dsRNA(Alu repeat, 特定mRNA位点); 2)工程化: Zhang lab 2017开发REPAIR(dCas13b-ADAR2dd)→可编程A→I编辑; 3)挑战: REPAIR需递送大蛋白(~150kDa)→LNP/AAV瓶颈; 4)范式转换: 内源ADAR招募策略→仅需短ASO即可引导内源ADAR编辑靶RNA→无需递送外源蛋白; 5)Wave Life Sciences: stereopure ASO→精确招募ADAR1至SERPINA1 Z突变位点→A→I恢复正常蛋白; 6)WVE-006临床: 皮下注射ASO→简单安全可重复→治疗AATD; 7)意义: RNA编辑从工具到药物的转化。", "tags": ["ADAR", "RNA_editing", "WVE-006", "multi_hop"], "difficulty": "hard", "question_type": "multi_hop", "source": "literature", "required_modules": ["almanac", "retrieval"], "key_entities": ["ADAR", "REPAIR", "内源ADAR招募", "WVE-006", "ASO"], "evidence_dois": [], "language": "zh"}
{"id": "T01", "question": "2023-2025年碱基编辑领域最重要的3项临床进展", "answer": "1)2022-2023: VERVE-101(首个体内碱基编辑FIH试验)Phase Ib数据公布→LDL↓55%验证ABE+LNP体内平台; 2)2024: Beam Therapeutics BEAM-101(SCD的ABE疗法)进入Phase I/II→首个离体碱基编辑临床; 3)2024-2025: CBE进入临床(如Korro Bio KRRO-110)→碱基编辑全面进入临床时代。这三年碱基编辑从实验室技术跃升为临床治疗工具。", "tags": ["base_editing", "timeline", "2023-2025"], "difficulty": "medium", "question_type": "temporal", "source": "GEAlmanac", "required_modules": ["almanac", "retrieval"], "key_entities": ["VERVE-101", "BEAM-101", "碱基编辑", "临床进展"], "evidence_dois": [], "language": "zh"}
{"id": "T02", "question": "CRISPR基因编辑的关键里程碑时间线(2012-2025)", "answer": "2012: Jinek/Doudna/Charpentier证明Cas9可编程切割DNA(Science); 2013: Zhang/Church在哺乳细胞中实现编辑; 2016: David Liu开发碱基编辑(CBE); 2017: ABE; 2018: He Jiankui基因编辑婴儿事件; 2019: Prime Editing发表; 2020: 诺贝尔化学奖; 2020: 首例体内CRISPR给药(EDIT-101 LCA10); 2021: NTLA-2001 NEJM发表; 2022: VERVE-101首例碱基编辑FIH; 2023.12: Casgevy FDA获批; 2024: PM359首个PE IND; 2025: RNA编辑进入临床。", "tags": ["timeline", "milestones", "CRISPR"], "difficulty": "medium", "question_type": "temporal", "source": "GEAlmanac", "required_modules": ["almanac"], "key_entities": ["2012", "2016", "2019", "2020", "2023", "Casgevy", "诺贝尔奖"], "evidence_dois": [], "language": "zh"}
{"id": "T03", "question": "递送技术从AAV到LNP的技术演进时间线", "answer": "2008: Zolgensma前体AAV9基因治疗(Kaspar lab); 2012: Glybera成为首个获批基因治疗(AAV, EMA); 2017: Spark Luxturna(AAV2→视网膜)FDA获批; 2018: Alnylam patisiran(siRNA-LNP→肝脏)FDA获批→LNP平台验证; 2019: Zolgensma(AAV9高剂量IV)获批但伴随肝毒性; 2020-2021: AAV高剂量安全事件频发→行业反思; 2021: NTLA-2001(CRISPR-LNP)NEJM→LNP递送CRISPR验证; 2022-2025: LNP成为体内基因编辑首选载体，AAV限于局部给药。", "tags": ["delivery", "AAV", "LNP", "timeline"], "difficulty": "medium", "question_type": "temporal", "source": "expert_knowledge", "required_modules": ["delivery_tree", "almanac", "retrieval"], "key_entities": ["AAV", "LNP", "patisiran", "NTLA-2001", "Zolgensma"], "evidence_dois": [], "language": "zh"}
{"id": "T04", "question": "基因编辑治疗遗传性血液病的临床进展时间线", "answer": "2019: CTX001(后命名Casgevy)首例SCD患者给药→VictoriaGray痛苦发作完全消失; 2021: CTX001 TDT患者输血依赖消除; 2023.11: UK MHRA首次批准Casgevy; 2023.12: FDA批准Casgevy(SCD+TDT); 2024.1: Lyfgenia(慢病毒)也获FDA批准TDT; 2024: BEAM-101(ABE+SCD) Phase I/II; 2024: EMA批准Casgevy; 2025: 碱基编辑和Prime Editing方案进入血液病临床前/临床阶段。基因编辑血液病治疗从概念到获批用了约7年。", "tags": ["blood_disease", "SCD", "TDT", "timeline"], "difficulty": "medium", "question_type": "temporal", "source": "GEAlmanac", "required_modules": ["almanac", "retrieval"], "key_entities": ["Casgevy", "Victoria Gray", "BEAM-101", "SCD", "TDT"], "evidence_dois": [], "language": "zh"}
{"id": "T05", "question": "David Liu实验室在精确编辑技术上的发展轨迹", "answer": "2016: CBE(BE1→BE3→BE4): APOBEC+nCas9+UGI→C→T编辑; 2017: ABE(ABE7.10): 进化TadA+nCas9→A→G编辑(Nature 2017); 2019: Prime Editing(PE1→PE2/PE3): nCas9-RT+pegRNA→任意小编辑(Nature 2019); 2020: ABE8e(TadA-8e): 590x活性提升; 2022: epegRNA: 3'保护结构→PE效率3-4x; 2023: PE5max(MLH1dn+PEmax): PE效率→60%+; 2024: PACE/PANCE持续进化更优编辑器; 2025: 正在开发基因组大片段操作(PASTE, twin-PE)。每2-3年一代重大突破。", "tags": ["David_Liu", "base_editing", "prime_editing", "timeline"], "difficulty": "hard", "question_type": "temporal", "source": "expert_knowledge", "required_modules": ["almanac", "retrieval"], "key_entities": ["David Liu", "CBE", "ABE", "Prime Editing", "PE5max"], "evidence_dois": [], "language": "zh"}
{"id": "T06", "question": "基因编辑农业应用的全球监管演变时间线", "answer": "2016: 美国USDA确认CRISPR编辑蘑菇(不含外源DNA)不需要GMO审批; 2018: 欧洲法院裁定基因编辑作物受GMO法规约束; 2019: Calyxt高油酸大豆美国商业化; 2020: 阿根廷建立SDN-1豁免GMO框架; 2021: 日本Sicilian Rouge高GABA番茄上市; 2022: 中国发布基因编辑植物安全评价指南; 2023: EU委员会提案放宽SDN-1/SDN-2管制(待通过); 2024: 英国Genetic Technology Act生效; 2025: 全球去监管化趋势加速，但EU仍在讨论中。", "tags": ["agriculture", "regulation", "timeline"], "difficulty": "medium", "question_type": "temporal", "source": "expert_knowledge", "required_modules": ["retrieval", "patent"], "key_entities": ["USDA", "EU", "日本", "SDN-1", "GMO监管"], "evidence_dois": [], "language": "zh"}
{"id": "T07", "question": "RNA编辑疗法从发现到临床的时间线", "answer": "1987: 发现ADAR(腺苷脱氨酶)天然RNA编辑; 2017: Zhang lab REPAIR系统(dCas13-ADAR2dd); 2019: RESCUE(C-to-U RNA编辑); 2020: 内源ADAR招募策略概念验证(Merkle 2019); 2021-2022: Wave/Korro等公司开发治疗性ASO; 2023: WVE-006(Wave)进入Phase I(AATD); 2024: KRRO-110(Korro)进入临床; 2025: 多家RNA编辑公司获大额融资→领域进入临床验证阶段。从发现ADAR到临床用了~36年。", "tags": ["RNA_editing", "ADAR", "timeline"], "difficulty": "medium", "question_type": "temporal", "source": "expert_knowledge", "required_modules": ["almanac", "retrieval"], "key_entities": ["ADAR", "REPAIR", "RESCUE", "WVE-006", "KRRO-110"], "evidence_dois": [], "language": "zh"}
{"id": "T08", "question": "What is the timeline of key clinical milestones for in vivo gene editing?", "answer": "2020.03: EDIT-101 (AAV+SaCas9, retinal injection) first in-human in vivo CRISPR dose; 2021.06: NTLA-2001 (LNP+Cas9, IV) TTR knockdown 87% data published in NEJM; 2022.07: VERVE-101 first in-human in vivo base editing dose; 2023: NTLA-3001 (KLKB1 KO for HAE) Phase I data shows >90% target protein reduction; 2024: PM359 first prime editing IND approved; 2025: Multiple in vivo programs in Phase II/III. Paradigm shift from ex vivo to in vivo editing is well underway.", "tags": ["in_vivo", "clinical", "timeline"], "difficulty": "medium", "question_type": "temporal", "source": "GEAlmanac", "required_modules": ["almanac", "retrieval"], "key_entities": ["EDIT-101", "NTLA-2001", "VERVE-101", "PM359", "in vivo"], "evidence_dois": [], "language": "en"}
{"id": "T09", "question": "CRISPR知识产权纠纷的关键时间节点", "answer": "2012: Doudna/Charpentier发表CRISPR论文→UC Berkeley申请专利; 2013: Zhang lab发表哺乳细胞编辑→Broad Institute优先申请专利; 2014-2017: USPTO专利干涉程序(interference)→Broad获胜(独立发明); 2018: PTAB确认Broad专利有效; 2022: CAFC裁定Broad真核CRISPR专利不干涉Berkeley原核专利→两家各有势力范围; 2023-2025: 全球专利许可格局稳定→ERS Genomics(Doudna)和Broad分别授权商业许可。对产业化影响：双重许可增加了商业化成本。", "tags": ["patent", "IP", "timeline"], "difficulty": "medium", "question_type": "temporal", "source": "expert_knowledge", "required_modules": ["patent", "retrieval"], "key_entities": ["Broad", "UC Berkeley", "专利", "USPTO", "许可"], "evidence_dois": [], "language": "zh"}
{"id": "T10", "question": "CAR-T细胞治疗中基因编辑整合的演进时间线", "answer": "2017: 首个CRISPR编辑T细胞进入人体(Lu You, 中国, PD-1 KO); 2019: UPenn PD-1+TCR双KO T细胞试验(Stadtmauer 2020 Science); 2020: CTX110(allo CAR-T) Phase I开始; 2021: CRISPR-Cas9多重编辑CAR-T(TRAC+B2M+PD-1三KO)概念验证; 2022: Caribou CB-010(Cas12a编辑allo-CAR-T)进入临床; 2023-2024: Beam/Prime等新编辑器应用于CAR-T制造; 2025: 下一代基因编辑CAR-T(碱基编辑精准敲入、CRISPR筛选优化)进入管线。", "tags": ["CAR-T", "CRISPR", "timeline"], "difficulty": "medium", "question_type": "temporal", "source": "literature", "required_modules": ["almanac", "retrieval"], "key_entities": ["CRISPR CAR-T", "CTX110", "CB-010", "PD-1", "多重编辑"], "evidence_dois": [], "language": "zh"}
{"id": "SD09", "question": "如何设计一个针对视网膜遗传病的CRISPR基因编辑方案？", "answer": "方案: 1)诊断: 确定致病基因和突变(如CEP290 IVS26, RHO P23H); 2)编辑策略: 大突变→NHEJ切除(EDIT-101方案); 点突变→ABE/PE; 功能缺失→AAV基因补充; 3)编辑器选择: SaCas9(较小,适配单AAV); 4)递送: AAV5视网膜下注射(RPE嗜性)或AAV2(光感受器嗜性), 注射量50-300μL; 5)优势: 眼是免疫豁免器官→免疫反应低; 微量递送→全身暴露极小; 6)终点: OCT视网膜结构、ERG电生理、FST全视野刺激、最佳矫正视力(BCVA)。", "tags": ["retinal", "AAV", "strategy_design"], "difficulty": "hard", "question_type": "strategy_design", "source": "expert_knowledge", "required_modules": ["delivery_tree", "variant_resolver", "retrieval"], "key_entities": ["视网膜", "AAV5", "SaCas9", "CEP290", "注射"], "evidence_dois": [], "language": "zh"}
{"id": "SD10", "question": "设计一个最小化脱靶的碱基编辑实验方案", "answer": "方案: 1)sgRNA选择: CFD score>0.9, 编辑窗口内仅单一目标碱基; 2)编辑器: ABE8e-V106W(降低RNA脱靶)+HiFi Cas9(降低DNA脱靶); 3)递送: RNP电穿孔(瞬时,12h内降解vs mRNA 24h vs质粒持续表达); 4)剂量优化: 滴定RNP浓度(过高增加脱靶); 5)检测: Amplicon-seq(on+top10 off)、GUIDE-seq(全基因组)、RNA-seq(转录组脱靶); 6)对照: 使用non-targeting sgRNA排除随机背景; 7)标准: DNA脱靶<0.1%, RNA脱靶<0.01%。", "tags": ["off_target", "base_editing", "strategy_design"], "difficulty": "hard", "question_type": "strategy_design", "source": "expert_knowledge", "required_modules": ["safety_firewall", "variant_resolver", "retrieval"], "key_entities": ["V106W", "HiFi", "RNP", "GUIDE-seq", "CFD"], "evidence_dois": [], "language": "zh"}
{"id": "SD11", "question": "如何为一个新发现的单基因遗传病建立基因编辑治疗研究路线图？", "answer": "路线图: Phase 0(6月): 基因/突变确认(WES/WGS)→ClinVar注册→编辑策略in silico设计→sgRNA筛选; Phase 1(12月): 细胞系验证(患者iPSC→靶细胞分化)→编辑效率+脱靶GUIDE-seq→功能rescue验证; Phase 2(12月): 动物模型(KI小鼠或NHP)→体内递送优化→PK/PD/安全性→组织学; Phase 3(18月): GLP毒理(2种动物)→GMP级生产→IND申报→监管互动; Phase 4: Phase I/II临床→长期随访。总周期:4-5年至IND。", "tags": ["roadmap", "translational", "strategy_design"], "difficulty": "hard", "question_type": "strategy_design", "source": "expert_knowledge", "required_modules": ["variant_resolver", "delivery_tree", "patent", "retrieval"], "key_entities": ["路线图", "iPSC", "动物模型", "GLP", "IND"], "evidence_dois": [], "language": "zh"}
{"id": "SD12", "question": "Design a multiplexed CRISPR editing strategy for allogeneic CAR-T manufacturing", "answer": "Strategy: 1) Targets: TRAC (prevent GvHD) + B2M (evade NK killing) + PD-1 (enhance persistence) + CISH (boost cytokine signaling); 2) Delivery: Cas12a with pre-crRNA array (4 spacers, single vector) via electroporation of RNP; 3) CAR integration: AAV6 donor template for HDR-mediated site-specific insertion at TRAC locus; 4) QC: flow cytometry (TCR-/B2M-/PD-1-/CAR+), WGS for translocations; 5) Scale: CliniMACS Prodigy automated manufacturing; 6) Anticipated outcomes: quadruple KO efficiency >60%, CAR+ >70%.", "tags": ["CAR-T", "multiplexed", "Cas12a", "strategy_design"], "difficulty": "hard", "question_type": "strategy_design", "source": "expert_knowledge", "required_modules": ["almanac", "retrieval"], "key_entities": ["TRAC", "B2M", "PD-1", "Cas12a", "multiplexed"], "evidence_dois": [], "language": "en"}
{"id": "MH09", "question": "从碱基编辑器的蛋白工程演进看编辑效率和特异性的权衡关系", "answer": "演进: 1)ABE7.10(2017): wtTadA+TadA*异二聚体→效率20-40%, RNA脱靶中等; 2)ABE8e(2020): TadA-8e单体→590x体外活性→效率50-70%→但RNA脱靶增加; 3)ABE8e-V106W: V106W点突变→RNA脱靶↓10x→但on-target效率略降(~10%); 4)ABE9(hypothetical): 持续进化中。权衡: 催化活性↑→on-target↑但off-target也↑→需要在活性-特异性空间中找帕累托最优。Liu lab使用phage-assisted continuous evolution (PACE)在这个空间中搜索。", "tags": ["ABE", "protein_engineering", "multi_hop"], "difficulty": "hard", "question_type": "multi_hop", "source": "literature", "required_modules": ["retrieval", "almanac"], "key_entities": ["ABE7.10", "ABE8e", "V106W", "PACE", "权衡"], "evidence_dois": [], "language": "zh"}
{"id": "MH10", "question": "从Alnylam的siRNA-LNP到Intellia的CRISPR-LNP，追溯肝脏递送平台的传承和创新", "answer": "传承: 1)2018 Alnylam patisiran(FDA获批): 验证MC3-LNP(DLin-MC3-DMA)肝脏递送siRNA可行; 2)递送机制: ApoE吸附→LDLR→内体逃逸被完整阐明; 3)Intellia继承: 采用类MC3可电离脂质→包裹Cas9 mRNA(~4500nt)而非siRNA(~21nt); 创新: 4)载荷差异: mRNA比siRNA大200倍→需优化脂质:RNA ratio和PEG比例; 5)双载荷: 同时包裹Cas9 mRNA+sgRNA→两种RNA需协同释放; 6)瞬时vs持续: siRNA需重复给药,CRISPR单次永久→安全窗口可更窄; 7)验证: NTLA-2001 87%TTR↓。", "tags": ["LNP", "Alnylam", "Intellia", "multi_hop"], "difficulty": "hard", "question_type": "multi_hop", "source": "literature", "required_modules": ["delivery_tree", "almanac", "retrieval"], "key_entities": ["patisiran", "MC3", "NTLA-2001", "mRNA", "siRNA"], "evidence_dois": [], "language": "zh"}
{"id": "MH11", "question": "CRISPR从诺贝尔奖(2020)到首个获批疗法(2023)的关键转化节点", "answer": "节点: 1)2020诺奖→全球关注→资本涌入; 2)2021.06 NTLA-2001 NEJM→体内CRISPR可行性震惊学界; 3)2021-2022 Casgevy(CTX001) Phase I/II: SCD患者>97% HbF+, 完全无VOC; 4)2022.11 CRISPR/Vertex向FDA提交BLA; 5)2023.06 FDA ODAC会议→一致推荐批准; 6)2023.11.16 UK MHRA全球首批; 7)2023.12.08 FDA批准SCD适应症; 8)2024.01 FDA批准TDT适应症。关键加速因子: Breakthrough Therapy+RMAT双重资格、Victoria Gray(首例患者)长期数据完美。", "tags": ["Casgevy", "Nobel", "FDA", "multi_hop"], "difficulty": "hard", "question_type": "multi_hop", "source": "GEAlmanac", "required_modules": ["almanac", "retrieval"], "key_entities": ["诺贝尔奖", "NTLA-2001", "Casgevy", "FDA", "Victoria Gray"], "evidence_dois": [], "language": "zh"}
{"id": "MH12", "question": "从HDR效率瓶颈到碱基编辑和先导编辑的技术创新路径", "answer": "瓶颈: HDR在临床相关细胞(HSC/T cell/neuron)中效率<10%→因为: NHEJ竞争+细胞周期限制+供体递送困难。解决路径1: 碱基编辑(2016)→nCas9+脱氨酶→无DSB→不依赖HDR→效率50-70%→但仅限4种转换。解决路径2: 先导编辑(2019)→nCas9-RT→pegRNA模板→无DSB+无HDR→灵活但效率低→PE5max+epegRNA提升至60%。解决路径3: HITI(2016)→利用NHEJ非HDR在非分裂细胞中敲入→适合post-mitotic。每条路径解决HDR不同方面的限制。", "tags": ["HDR", "base_editing", "prime_editing", "HITI", "multi_hop"], "difficulty": "hard", "question_type": "multi_hop", "source": "literature", "required_modules": ["retrieval", "almanac"], "key_entities": ["HDR", "碱基编辑", "先导编辑", "HITI", "效率"], "evidence_dois": [], "language": "zh"}
{"id": "T11", "question": "基因编辑伦理治理的主要国际事件时间线", "answer": "2015: 第一届人类基因组编辑峰会(Washington)→讨论临床应用边界; 2017: NAS/NAM报告允许体细胞编辑+限制生殖系; 2018.11: He Jiankui宣布基因编辑婴儿→全球震惊; 2019: He Jiankui被判入狱3年; 2020: WHO成立Expert Advisory Committee; 2021: WHO发布全球治理框架; 2023: 第三届峰会(London)→重申生殖系moratorium; 2024: 多国更新基因编辑立法; 2025: 国际社会继续讨论渐进式放开生殖系研究。", "tags": ["ethics", "governance", "timeline"], "difficulty": "medium", "question_type": "temporal", "source": "expert_knowledge", "required_modules": ["retrieval"], "key_entities": ["He Jiankui", "WHO", "伦理峰会", "moratorium"], "evidence_dois": [], "language": "zh"}
{"id": "T12", "question": "高保真Cas9变体的发展时间线", "answer": "2016: eSpCas9(1.1)(Slaymaker,能量减少→脱靶↓); 2016: SpCas9-HF1(Kleinstiver,破坏非靶链接触→减少脱靶); 2017: HypaCas9(hyper-accurate); 2018: evoCas9(噬菌体辅助进化); 2019: Sniper-Cas9(Cas9负选择进化); 2020: SuperFi-Cas9(mismatch sensing↑); 2021: Cas9-NRCH(Kim,放宽PAM); 2021-2023: prime editor中nCas9也在进化→PEmax; 2025: AI辅助Cas9蛋白设计→高保真+高活性兼顾。趋势：从rational design→directed evolution→AI design。", "tags": ["high_fidelity", "Cas9", "timeline"], "difficulty": "medium", "question_type": "temporal", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["eSpCas9", "HF1", "HypaCas9", "SuperFi", "AI"], "evidence_dois": [], "language": "zh"}
{"id": "F26", "question": "什么是PASTE(Programmable Addition via Site-specific Targeting Elements)？", "answer": "PASTE是David Liu团队2022年开发的大片段DNA插入技术。利用PE在基因组特定位点安装噬菌体att位点→丝氨酸整合酶(Bxb1)催化att重组→实现大片段DNA(可达>36kb)定点插入。关键优势：无DSB、大容量、效率5-15%。限制：需两步反应(PE+整合酶)、效率仍需提高。", "tags": ["PASTE", "large_insertion", "mechanism"], "difficulty": "hard", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["PASTE", "Bxb1", "att位点", "大片段插入"], "evidence_dois": [], "language": "zh"}
{"id": "F27", "question": "Zolgensma(onasemnogene abeparvovec)的剂量和给药方式是什么？", "answer": "Zolgensma: AAV9载体递送SMN1基因，一次性静脉注射，剂量1.1×10^14 vg/kg(约2-5mL/kg)。适用于<2岁SMA 1型患者。是目前AAV基因治疗中单次给药剂量最高的产品之一，也因此引发肝毒性安全信号。定价约210万美元/次。", "tags": ["Zolgensma", "AAV9", "SMA", "factual"], "difficulty": "easy", "question_type": "factual", "source": "literature", "required_modules": ["retrieval", "delivery_tree"], "key_entities": ["Zolgensma", "AAV9", "SMN1", "1.1×10^14", "SMA"], "evidence_dois": [], "language": "zh"}
{"id": "F28", "question": "什么是DISCOVER-seq？它在脱靶检测中有什么独特优势？", "answer": "DISCOVER-seq(Discovery of in situ Cas off-targets and verification by sequencing)利用DNA修复标记蛋白MRE11在DSB位点的快速募集。ChIP-seq MRE11后测序→检测体内真实DSB位点。独特优势:检测体内实际发生的脱靶(而非体外人工条件下)，最接近真实治疗情境。局限:灵敏度依赖ChIP效率。", "tags": ["DISCOVER-seq", "off_target", "methods"], "difficulty": "medium", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["DISCOVER-seq", "MRE11", "ChIP-seq", "体内脱靶"], "evidence_dois": [], "language": "zh"}
{"id": "F29", "question": "Cas9 nickase(nCas9)有哪两种常见突变？分别切割哪条链？", "answer": "nCas9(D10A): RuvC结构域失活→仅HNH切割互补链(与sgRNA配对的链); nCas9(H840A): HNH结构域失活→仅RuvC切割非互补链。碱基编辑通常使用D10A(nick互补链→引导细胞修复非编辑链); Prime Editing使用H840A(nick非互补链→释放3'端供RT延伸)。", "tags": ["nCas9", "nickase", "mechanism"], "difficulty": "medium", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["D10A", "H840A", "RuvC", "HNH", "nickase"], "evidence_dois": [], "language": "zh"}
{"id": "F30", "question": "什么是twin-PE？它能实现什么类型的基因组编辑？", "answer": "twin-PE(twin prime editing)使用两个pegRNA分别在靶位点两侧进行prime editing，合成两条互补的DNA flap→flap退火→替换两个切口之间的序列。可实现: 大片段替换(数百bp)、精确缺失、定向倒位。配合重组酶(如Bxb1)可实现>10kb大片段整合。2021年Anzalone Nature Biotechnology发表。", "tags": ["twin-PE", "prime_editing", "large_edit"], "difficulty": "hard", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["twin-PE", "pegRNA", "flap退火", "Bxb1"], "evidence_dois": [], "language": "zh"}
{"id": "S14", "question": "基因驱动(Gene Drive)技术的安全和生态伦理问题", "answer": "基因驱动利用CRISPR使特定等位基因以超孟德尔比率(>50%)传递→可覆盖整个种群。应用: 消灭疟蚊(Anopheles gambiae dsxF KO)。安全/伦理问题: 1)不可逆生态影响(物种灭绝→食物链崩溃); 2)基因逃逸到近缘种; 3)无法召回(一旦释放不可控); 4)单方面决策影响全球生态; 5)生物武器潜在风险。缓解: daisy chain drive(自限性)、split drive(分离表达)→非自持扩散。", "tags": ["gene_drive", "ecology", "safety", "ethics"], "difficulty": "hard", "question_type": "safety", "source": "expert_knowledge", "required_modules": ["safety_firewall", "retrieval"], "key_entities": ["基因驱动", "疟蚊", "超孟德尔", "自限性", "生态"], "evidence_dois": [], "language": "zh"}
{"id": "S15", "question": "What are the safety concerns of long-term dCas9 expression in CRISPRi/a therapeutics?", "answer": "Concerns: 1) Sustained bacterial protein expression→chronic immune stimulation (anti-Cas9 T cells in ~50% humans); 2) Potential genomic occupancy effects: dCas9 binding may interfere with nearby gene regulation; 3) Insertional mutagenesis if delivered via integrating vector (lentivirus); 4) Loss of efficacy over time (silencing of expression cassette); 5) Need for lifelong expression vs one-time DNA editing. Mitigations: non-integrating AAV delivery, regulatable promoters (Tet-ON), RNA-based transient approaches being explored.", "tags": ["CRISPRi", "dCas9", "long_term", "safety"], "difficulty": "hard", "question_type": "safety", "source": "literature", "required_modules": ["safety_firewall", "retrieval"], "key_entities": ["dCas9", "chronic expression", "immune", "insertional mutagenesis"], "evidence_dois": [], "language": "en"}
{"id": "MH13", "question": "碱基编辑从实验室发明到首个临床试验，涉及哪些学科交叉和关键技术突破？", "answer": "学科交叉: 1)化学生物学: TadA脱氨酶定向进化(PACE); 2)结构生物学: Cas9-DNA复合物冷冻电镜结构→指导编辑窗口设计; 3)RNA化学: sgRNA化学修饰(2'-OMe, PS)→提高体内稳定性; 4)纳米医学: LNP配方优化(可电离脂质筛选,microfluidic mixing); 5)免疫学: 抗Cas9预存免疫分析; 6)基因组学: 全基因组脱靶检测技术; 7)临床医学: 剂量递增试验设计; 8)药学: mRNA GMP生产工艺。每个环节的突破都是临床转化的必要条件。", "tags": ["base_editing", "interdisciplinary", "multi_hop"], "difficulty": "hard", "question_type": "multi_hop", "source": "expert_knowledge", "required_modules": ["almanac", "retrieval"], "key_entities": ["PACE", "冷冻电镜", "化学修饰", "LNP", "GMP"], "evidence_dois": [], "language": "zh"}
{"id": "MH14", "question": "为什么SCD(镰刀细胞病)成为基因编辑首个获批适应症？追溯原因", "answer": "原因链: 1)未满足需求: SCD患者pain crisis严重影响生活，无根治药物; 2)单基因: 唯一突变(HBB E6V)→明确靶标; 3)天然验证: HPFH(遗传性胎儿血红蛋白持续症)个体证明HbF↑可代偿→BCL11A KO策略有天然Human POC; 4)ex vivo成熟: HSC编辑流程(CD34+动员→电穿孔→回输)已被基因治疗领域验证; 5)小样本量: orphan disease→Phase III可<100例→审批快; 6)监管优惠: Breakthrough+RMAT资格; 7)戏剧性疗效: Victoria Gray zero pain crisis→情感说服力+数据说服力。", "tags": ["SCD", "Casgevy", "why_first", "multi_hop"], "difficulty": "hard", "question_type": "multi_hop", "source": "expert_knowledge", "required_modules": ["almanac", "retrieval"], "key_entities": ["SCD", "HBB", "BCL11A", "HPFH", "Victoria Gray"], "evidence_dois": [], "language": "zh"}
{"id": "SD13", "question": "如何设计碱基编辑的旁观者编辑最小化方案？", "answer": "方案: 1)位点选择: 优先选择编辑窗口(pos 4-8)内仅含单一靶碱基A/C的位点; 2)编辑器选择: ABE8e(窗口更窄,4-7) > ABE7.10(窗口4-8); 3)PAM方向: 尝试反向互补链设计→将靶碱基放在窗口中心; 4)工程化: ABE-CP(circular permutation)变体可移动窗口位置; 5)Prime Editing备选: 如果所有BE设计都有旁观者问题→PE可精确到单碱基; 6)验证: Amplicon-seq查看窗口内每个碱基的编辑率; 7)报告: 区分编辑产物(仅靶标 vs 靶标+旁观者)比例。", "tags": ["bystander", "base_editing", "strategy_design"], "difficulty": "hard", "question_type": "strategy_design", "source": "expert_knowledge", "required_modules": ["variant_resolver", "retrieval"], "key_entities": ["旁观者编辑", "编辑窗口", "ABE8e", "circular permutation"], "evidence_dois": [], "language": "zh"}
{"id": "SD14", "question": "为资源有限的发展中国家设计可及性高的基因编辑治疗方案", "answer": "方案: 1)简化编辑流程: 使用RNP电穿孔(无需病毒生产设施)+自动化封闭系统(CliniMACS Prodigy); 2)降低清髓毒性: 开发非基因毒性预处理(anti-CD117单抗替代白消安); 3)体内编辑优先: LNP-mRNA一次性IV给药(无需复杂细胞制备设施); 4)通用型产品: 异体CAR-T/编辑HSC批量生产+全球分发; 5)定价: 分期付款+价值评价定价; 6)区域GMP中心: 在非洲/东南亚建立区域制造中心; 7)临床试验外移: 在高发地区(撒哈拉以南非洲SCD高发区)开展试验。", "tags": ["access", "equity", "strategy_design"], "difficulty": "hard", "question_type": "strategy_design", "source": "expert_knowledge", "required_modules": ["almanac", "delivery_tree", "retrieval"], "key_entities": ["可及性", "发展中国家", "LNP", "通用型", "CliniMACS"], "evidence_dois": [], "language": "zh"}
{"id": "MH15", "question": "从sgRNA设计到临床疗效，追溯Casgevy BCL11A编辑的全优化链", "answer": "优化链: 1)靶点: BCL11A +58 erythroid enhancer(而非编码区→保留其他组织功能); 2)sgRNA: 高效切割+低脱靶→Doench score>0.7, GUIDE-seq验证top20 off-target均<0.1%; 3)递送: RNP电穿孔(Cas9蛋白4μg+sgRNA12μg/10^6 cells)→编辑效率>90% at locus; 4)HSC培养: StemSpan+SCF+TPO+Flt3L→维持HSC stemness; 5)冻存: 编辑后细胞-80°C→运输→解冻回输; 6)疗效: HbF>20%(SCD不再镰变的阈值)→实际达40-50%→VOC完全消除。每一步的优化都是必要的。", "tags": ["Casgevy", "BCL11A", "optimization", "multi_hop"], "difficulty": "hard", "question_type": "multi_hop", "source": "literature", "required_modules": ["almanac", "retrieval"], "key_entities": ["BCL11A", "+58增强子", "RNP", "HbF", "VOC"], "evidence_dois": [], "language": "zh"}
{"id": "T13", "question": "基因编辑在肝脏疾病治疗中的临床进展时间线", "answer": "2019: NTLA-2001 IND(hATTR, TTR KO); 2021.06: Phase I发表NEJM, TTR↓87%; 2022: VERVE-101(HeFH, PCSK9 BE)首例给药; 2023: NTLA-3001(HAE, KLKB1 KO)Phase I数据→靶蛋白↓>90%; 2024: VERVE-101 Phase Ib扩展数据LDL↓55%; 2024-2025: 新靶点进入管线(ANGPTL3→高甘油三酯, HPD→酪氨酸血症, FAH→HT1)。肝脏基因编辑从一个靶点扩展到多个肝脏代谢病，LNP平台验证后管线快速扩张。", "tags": ["liver", "clinical", "timeline"], "difficulty": "medium", "question_type": "temporal", "source": "GEAlmanac", "required_modules": ["almanac", "retrieval"], "key_entities": ["NTLA-2001", "VERVE-101", "NTLA-3001", "肝脏", "LNP"], "evidence_dois": [], "language": "zh"}
{"id": "F31", "question": "什么是CFD(Cutting Frequency Determination) score？", "answer": "CFD score由Doench 2016年开发，量化sgRNA-DNA错配对Cas9切割频率的影响。取值0-1，1代表完全匹配的切割频率。计算基于大规模实验测定的每个位置每种错配类型的切割频率矩阵。CFD用于评估脱靶位点的切割风险——CFD>0.5表示该脱靶位点有显著切割可能，需实验验证。", "tags": ["CFD", "off_target", "metrics"], "difficulty": "medium", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["CFD score", "Doench", "错配", "切割频率"], "evidence_dois": [], "language": "zh"}
{"id": "F32", "question": "AAVS1安全港位点的特征和在基因编辑中的应用", "answer": "AAVS1(PPP1R12C基因内含子1)位于chr19q13.42，是AAV2天然整合热点。特征: 1)开放染色质→可维持长期高表达; 2)远离已知致癌基因; 3)破坏PPP1R12C未发现不良表型。应用: CRISPR HDR在AAVS1定点敲入治疗基因或报告基因→避免随机整合的插入致突变风险。限制: 并非所有细胞类型中表达均强。", "tags": ["AAVS1", "safe_harbor", "knockin"], "difficulty": "medium", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["AAVS1", "PPP1R12C", "安全港", "chr19"], "evidence_dois": [], "language": "zh"}
{"id": "S16", "question": "基因编辑在非人灵长类(NHP)安全性研究中的常见发现", "answer": "NHP研究常见发现: 1)肝脏编辑(LNP): 一过性ALT/AST升高(通常1-2级,1周内恢复)、轻度血小板减少; 2)AAV高剂量: 肝毒性(ALT>正常10倍)、DRG(背根神经节)炎症/坏死; 3)编辑效率: NHP肝脏LNP编辑率通常比小鼠低20-30%(绝对值); 4)免疫: 抗Cas9 T细胞和抗体产生(mRNA/RNP递送免疫反应较AAV低); 5)NHP特有: 部分脱靶位点与人类不共享(基因组差异)→需额外人类细胞系验证。", "tags": ["NHP", "preclinical", "safety"], "difficulty": "hard", "question_type": "safety", "source": "literature", "required_modules": ["cross_species", "safety_firewall", "retrieval"], "key_entities": ["NHP", "ALT", "DRG", "转化", "脱靶"], "evidence_dois": [], "language": "zh"}
{"id": "F33", "question": "什么是CasRx(Cas13d)？它有什么独特优势？", "answer": "CasRx(RfxCas13d)是来自Ruminococcus flavefaciens的Cas13d变体，仅967个氨基酸(Cas13家族最小)。优势: 1)小型→可单AAV递送; 2)RNA切割活性高(>90% knockdown); 3)collateral activity在哺乳细胞中最低; 4)可用于RNA knockdown替代RNAi(无需Dicer); 5)已在动物模型中验证(Konermann 2018 Cell)。应用: RNA降解、RNA剪接调节、RNA成像。", "tags": ["CasRx", "Cas13d", "RNA"], "difficulty": "medium", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["CasRx", "Cas13d", "967aa", "RNA切割"], "evidence_dois": [], "language": "zh"}
{"id": "F34", "question": "什么是PACE(Phage-Assisted Continuous Evolution)？在基因编辑中的应用", "answer": "PACE由David Liu团队2011年开发，利用M13噬菌体在大肠杆菌中的持续感染周期(约10min/代)→实现蛋白质100+代/天的快速定向进化(约比传统方法快100倍)。在基因编辑中: 1)PACE进化TadA→ABE7.10(2017); 2)PACE进化ADAR2→RESCUE(C-to-U); 3)PACE进化BE→更高保真变体; 4)PACE进化RT→更高效PE。PACE是刘如谦团队工具开发的核心技术平台。", "tags": ["PACE", "directed_evolution", "David_Liu"], "difficulty": "hard", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["PACE", "M13噬菌体", "定向进化", "TadA", "100代/天"], "evidence_dois": [], "language": "zh"}
{"id": "F35", "question": "i53抑制剂在提高HDR效率中的作用机制", "answer": "i53是来自噬菌体的53BP1结合蛋白，通过结合53BP1的Tudor结构域阻止其识别DSB诱导的H4K20me2标记→53BP1无法募集至DSB位点→解除对末端切除的阻断→促进BRCA1/CtIP介导的长距离切除→产生3'ssDNA overhang→RAD51加载→HDR激活。i53可将HDR:NHEJ比率提高2-5倍。常以蛋白或mRNA形式与Cas9共递送。", "tags": ["i53", "53BP1", "HDR", "mechanism"], "difficulty": "hard", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["i53", "53BP1", "Tudor", "BRCA1", "HDR"], "evidence_dois": [], "language": "zh"}
{"id": "C26", "question": "SpCas9与AsCas12a在基因敲除应用中的比较", "answer": "SpCas9: PAM=NGG(任何N+GG), 产生平末端DSB, 编辑窗口宽→可嗜同源臂HDR。AsCas12a(Cpf1): PAM=TTTV(富AT区域), 产生5'突出粘性末端(4-5nt), 自带crRNA加工活性→天然适合多重编辑(单一crRNA array)。效率: SpCas9在多数位点>AsCas12a, 但AsCas12a在AT-rich区域(如启动子)更优。温度敏感性: AsCas12a在37°C活性下降→enAsCas12a(E174R/S542R/K548R)改善。总结: SpCas9更通用, AsCas12a更适合多重编辑和AT-rich靶标。", "tags": ["SpCas9", "AsCas12a", "comparison"], "difficulty": "medium", "question_type": "comparison", "source": "literature", "required_modules": ["almanac", "retrieval"], "key_entities": ["SpCas9", "AsCas12a", "PAM", "粘性末端", "多重编辑"], "evidence_dois": [], "language": "zh"}
{"id": "C27", "question": "AAV与LNP在体内基因编辑递送中的对比", "answer": "AAV: 优势→组织特异性强(多种血清型)、可感染非分裂细胞、长期表达; 劣势→包装<4.7kb(Cas9勉强)、持续表达增加脱靶、预存免疫(30-60%人群)、无法重复给药、DRG毒性。LNP: 优势→无包装限制(mRNA)、瞬时表达→脱靶窗口短、可重复给药、无预存免疫、GMP工艺成熟(COVID疫苗); 劣势→天然肝脏趋向性(非肝器官难递送)、首过效应、需冷链。趋势: LNP在肝脏基因编辑中已成主流; AAV仍统治CNS/眼/肌肉。", "tags": ["AAV", "LNP", "delivery", "comparison"], "difficulty": "medium", "question_type": "comparison", "source": "literature", "required_modules": ["delivery_tree", "retrieval"], "key_entities": ["AAV", "LNP", "包装", "免疫", "肝脏"], "evidence_dois": [], "language": "zh"}
{"id": "C28", "question": "Compare GUIDE-seq and CIRCLE-seq for off-target detection", "answer": "GUIDE-seq: In cellulo method→integrates dsODN at DSB sites→unbiased detection of real cellular off-targets; Pros: captures chromatin context, detects actual events; Cons: requires transfectable cells, sensitivity depends on dsODN integration efficiency, needs 10M+ reads. CIRCLE-seq: In vitro method→circularized genomic DNA cleaved by Cas9-sgRNA RNP→linearized fragments sequenced; Pros: highest sensitivity (detects extremely rare sites), no cell type limitation; Cons: no chromatin context→many sites won't be cleaved in cells (over-prediction), ~10x more false positives than GUIDE-seq. Recommendation: Use CIRCLE-seq for comprehensive nomination→GUIDE-seq or rhAmpSeq for cellular validation.", "tags": ["GUIDE-seq", "CIRCLE-seq", "off_target", "comparison"], "difficulty": "hard", "question_type": "comparison", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["GUIDE-seq", "CIRCLE-seq", "dsODN", "in vitro", "off-target"], "evidence_dois": [], "language": "en"}
{"id": "C29", "question": "CRISPR激活(CRISPRa)的SAM与SunTag系统比较", "answer": "SAM(Synergistic Activation Mediator): dCas9-VP64+MS2-p65-HSF1→MS2 coat protein结合sgRNA stem-loop→招募p65+HSF1→协同激活。SunTag: dCas9-10xGCN4→scFv-sfGFP-VP64识别GCN4表位→每个dCas9招募10个VP64。比较: SAM激活强度更高(~1000倍vs SunTag~100倍)、组分更多(3质粒); SunTag信号放大线性可预测、适合成像。VPR(VP64-p65-Rta)融合简化了组分但激活弱于SAM。CRISPRa普遍比过表达更生理(保留内源调控元件)。", "tags": ["CRISPRa", "SAM", "SunTag", "comparison"], "difficulty": "hard", "question_type": "comparison", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["SAM", "SunTag", "VP64", "CRISPRa", "激活"], "evidence_dois": [], "language": "zh"}
{"id": "M21", "question": "CRISPR-Cas9 R-loop形成的分子机制", "answer": "R-loop形成: 1)PAM识别: Cas9 PI结构域扫描dsDNA寻找NGG→解锁构象变化; 2)种子区域: sgRNA 3'端(PAM-proximal 10-12nt)首先与靶链配对→形成RNA:DNA异源双链; 3)链侵入: 配对从种子向5'端延伸→置换非靶链→形成完整R-loop(~20bp RNA:DNA + ssDNA泡); 4)检验点: 位置1-10(seed)严格→单错配阻断、位置11-20容忍1-2个错配; 5)构象激活: 完整R-loop→HNH结构域旋转~180°→切割互补链→RuvC切割非互补链。R-loop动力学(稳定性)直接决定on/off-target切割效率。", "tags": ["R-loop", "mechanism", "Cas9"], "difficulty": "hard", "question_type": "mechanism", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["R-loop", "PAM", "种子区域", "HNH旋转", "切割"], "evidence_dois": [], "language": "zh"}
{"id": "M22", "question": "腺嘌呤碱基编辑器(ABE)催化A·T到G·C转换的化学机制", "answer": "步骤: 1)Cas9(D10A)引导sgRNA结合靶位点,形成R-loop暴露编辑窗口(pos 4-8)内的单链DNA; 2)TadA*脱氨酶将腺嘌呤(A)脱氨为次黄嘌呤(I): 水解氨基→酮基; 3)I被DNA复制/修复机器读为G→I:T错配; 4)nCas9 nick互补链→刺激细胞MMR修复非编辑链(T→C); 5)修复完成: I:C→复制后→G:C。净效果: A:T→G:C。UGI不需要(那是CBE用的, 抑制UNG)。TadA*是从大肠杆菌tRNA脱氨酶TadA通过PACE演化而来。", "tags": ["ABE", "deamination", "mechanism"], "difficulty": "hard", "question_type": "mechanism", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["TadA", "腺嘌呤", "次黄嘌呤", "脱氨", "A-to-G"], "evidence_dois": [], "language": "zh"}
{"id": "M23", "question": "先导编辑(Prime Editing)逆转录的分子细节", "answer": "步骤: 1)pegRNA引导nCas9(H840A)结合靶位点→nick非互补链→产生3'free end; 2)pegRNA的PBS(primer binding site,~13nt)与nick产生的3'flap退火; 3)逆转录酶(M-MLV RT)以pegRNA的RTT(reverse transcription template)为模板, 3'flap为引物→合成新DNA(含编辑); 4)平衡: 新合成的3'flap与原始5'flap竞争→5'flap Endogenous被FEN1切除; 5)新3'flap连接→形成heteroduplex→MMR修复互补链→完成编辑。PE3: 额外nick互补链→偏向使用编辑链→效率提升3x。", "tags": ["prime_editing", "reverse_transcription", "mechanism"], "difficulty": "hard", "question_type": "mechanism", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["pegRNA", "PBS", "RTT", "M-MLV RT", "3'flap"], "evidence_dois": [], "language": "zh"}
{"id": "CL21", "question": "EDIT-101治疗Leber先天性黑蒙10型(LCA10)的临床设计", "answer": "EDIT-101(Editas Medicine): 1)靶标: CEP290基因IVS26隐性剪接突变→AAV5递送SaCas9+双sgRNA→切除致病内含子突变; 2)给药: 视网膜下注射(一次性); 3)剂量递增: 低/中/高三个剂量组(成人→儿童); 4)终点: 安全性(主要)+BCVA、FST、瞳孔光反射(次要); 5)进展: 2020首例给药→截至2023部分患者视力改善; 6)挑战: AAV5视网膜转导效率个体差异大、SaCas9持续表达免疫风险; 7)对照: 无(单臂开放标签)。", "tags": ["EDIT-101", "LCA10", "CEP290", "clinical"], "difficulty": "hard", "question_type": "clinical", "source": "GEAlmanac", "required_modules": ["almanac", "retrieval"], "key_entities": ["EDIT-101", "CEP290", "LCA10", "SaCas9", "视网膜"], "evidence_dois": [], "language": "zh"}
{"id": "CL22", "question": "EBT-101(HIV功能性治愈)的CRISPR策略和临床进展", "answer": "EBT-101(Excision BioTherapeutics): 1)策略: AAV9递送SaCas9+多重sgRNA→靶向HIV-1前病毒LTR+Gag→从宿主基因组中切除整合的前病毒; 2)挑战: HIV准种多样性→需多个sgRNA覆盖不同变异; 储库清除难(潜伏记忆CD4+ T cells); 3)给药: 单次IV注射; 4)Phase I(NCT05144386): 2022首例给药, 安全性+病毒储库监测; 5)终点: HIV DNA PCR、定量病毒生长测定(QVOA)、cART中断后病毒反弹延迟; 6)风险: AAV9全身分布→非靶器官Cas9表达。", "tags": ["EBT-101", "HIV", "functional_cure", "clinical"], "difficulty": "hard", "question_type": "clinical", "source": "literature", "required_modules": ["almanac", "retrieval"], "key_entities": ["EBT-101", "HIV", "前病毒", "LTR", "AAV9"], "evidence_dois": [], "language": "zh"}
{"id": "CL23", "question": "Verve Therapeutics VERVE-101碱基编辑降胆固醇的临床数据", "answer": "VERVE-101: 1)机制: LNP递送ABE mRNA+sgRNA→肝脏PCSK9基因引入W159X无义突变→永久性灭活PCSK9→LDL-R上调→LDL-C清除; 2)Phase Ib heart-1(HeFH患者): 单次0.45mg/kg→PCSK9↓84%→LDL-C↓55%(6月); 3)安全性: 一过性ALT升高(1-2级)、轻度血小板降低→均自行恢复; 4)突破性: 首个体内碱基编辑心血管适应症→从单基因罕见病扩展到常见代谢病; 5)竞品: 与PCSK9抗体(需每2周注射)、inclisiran siRNA(每半年1次)相比→一次性永久。", "tags": ["VERVE-101", "PCSK9", "base_editing", "clinical"], "difficulty": "hard", "question_type": "clinical", "source": "GEAlmanac", "required_modules": ["almanac", "variant_resolver", "retrieval"], "key_entities": ["VERVE-101", "PCSK9", "LDL-C", "碱基编辑", "HeFH"], "evidence_dois": [], "language": "zh"}
{"id": "CL24", "question": "What are the key clinical results from NTLA-3001 for hereditary angioedema?", "answer": "NTLA-3001 (Intellia): 1) Target: CRISPR KO of KLKB1 (prekallikrein) in liver→reduce kallikrein→prevent bradykinin-mediated angioedema attacks; 2) Phase I results: single IV dose of LNP-Cas9→plasma prekallikrein ↓>90%→angioedema attack rate ↓95%; 3) Durability: effects sustained >1 year in follow-up; 4) Safety: transient mild liver enzyme elevation, no serious AEs; 5) Significance: second LNP-CRISPR program (after NTLA-2001) validating the platform for multiple liver targets; 6) Competitive advantage over lanadelumab (anti-kallikrein mAb, biweekly injection)→one-time treatment.", "tags": ["NTLA-3001", "HAE", "KLKB1", "clinical"], "difficulty": "hard", "question_type": "clinical", "source": "GEAlmanac", "required_modules": ["almanac", "retrieval"], "key_entities": ["NTLA-3001", "KLKB1", "prekallikrein", "HAE", "LNP"], "evidence_dois": [], "language": "en"}
{"id": "T14", "question": "AAV基因治疗的关键安全事件时间线", "answer": "1999: Jesse Gelsinger死亡(AdV高剂量免疫风暴)→基因治疗领域冰冻期; 2020: Audentes AT132(X-linked myotubular myopathy) Phase I/II→3例患者死于肝衰竭(高剂量AAV8); 2021: Novartis Zolgensma上市后→多例TMA(血栓性微血管病)报告; 2022: FDA暂停多个高剂量AAV项目; 2022: Pfizer fordadistrogene→肌营养不良患者心脏死亡→FDA审查; 2023: FDA要求所有AAV基因治疗加入DRG毒性监测→自然杀手; 2024: 行业反思→剂量上限不宜超过3×10^14 vg/kg。AAV安全性成为领域核心关切。", "tags": ["AAV", "safety_event", "timeline"], "difficulty": "hard", "question_type": "temporal", "source": "expert_knowledge", "required_modules": ["failure_db", "safety_firewall", "retrieval"], "key_entities": ["Jesse Gelsinger", "AT132", "Zolgensma", "DRG", "AAV"], "evidence_dois": [], "language": "zh"}
{"id": "T15", "question": "RNA编辑技术(ADAR)的发展时间线", "answer": "2017: Cox/Zhang/Abudayyeh: REPAIRv1(dCas13b-ADAR2DD)→A-to-I RNA编辑; 2018: REPAIRv2(E488Q/T375G)→提高特异性; 2019: RESCUE(dCas13-ADAR2DD进化变体)→C-to-U RNA编辑; 2021: LEAPER(Leveraging Endogenous ADAR for Programmable Editing of RNA)→不需外源ADAR→仅用工程化长RNA招募内源ADAR; 2022: CLUSTER/PKR-based进化→提高效率; 2023-2024: Wave/Ascidian等公司推进ADAR ASO至临床→GalNAc-ASO肝脏递送; 2025: 多个ADAR RNA编辑疗法进入Phase I。RNA编辑是DNA编辑的可逆安全替代。", "tags": ["RNA_editing", "ADAR", "timeline"], "difficulty": "hard", "question_type": "temporal", "source": "literature", "required_modules": ["almanac", "retrieval"], "key_entities": ["REPAIR", "RESCUE", "LEAPER", "ADAR", "RNA编辑"], "evidence_dois": [], "language": "zh"}
{"id": "F36", "question": "什么是anti-CRISPR蛋白？有哪些代表性类型？", "answer": "Anti-CRISPR(Acr)蛋白是噬菌体进化产生的CRISPR抑制剂，可阻断Cas效应蛋白功能。代表类型: AcrIIA4→结合SpCas9 PAM互作界面→阻止DNA结合(最强抑制); AcrIIA2→模拟DNA与Cas9结合; AcrVA1→切割Cas12a crRNA; AcrIIC1→结合NmCas9 HNH结构域。应用价值: 1)编辑后灭活Cas→减少脱靶; 2)时序控制(先编辑→再关闭); 3)组织特异性关闭(AAV组织启动子驱动Acr)。", "tags": ["anti-CRISPR", "Acr", "regulation"], "difficulty": "hard", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["AcrIIA4", "AcrIIA2", "anti-CRISPR", "噬菌体"], "evidence_dois": [], "language": "zh"}
{"id": "F37", "question": "什么是microhomology-mediated end joining (MMEJ)?", "answer": "MMEJ(也称alt-EJ)是DSB修复的第三条通路(除NHEJ和HDR外)。机制: CtIP有限切除→暴露2-25bp微同源序列→退火→填充→连接。特点: 1)产生可预测的缺失(微同源序列之间的片段丢失); 2)不需要大同源臂(区别于HDR); 3)S/G2期活跃。基因编辑应用: inDelphi/FORECasT等工具可预测MMEJ修复结果→设计产生移码的sgRNA; MMEJ还用于无模板精确敲入(PITCH方法)。", "tags": ["MMEJ", "alt-EJ", "DNA_repair"], "difficulty": "hard", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["MMEJ", "微同源", "CtIP", "inDelphi", "PITCH"], "evidence_dois": [], "language": "zh"}
{"id": "F38", "question": "什么是retron editing？它有什么优势？", "answer": "Retron editing利用细菌retron(逆转录子)在体内产生单链DNA供体。原理: retron RT在胞内将msr-msd RNA逆转录为mcDNA(多拷贝ssDNA)→作为HDR同源模板→与Cas9共表达→实现精确编辑。优势: 1)供体在细胞内原位产生→不需外源合成供体; 2)持续产生供体→HDR效率更高更持久; 3)在细菌和酵母中验证效率极高; 4)2021 Sharon/Shipman Nature Methods。限制: 哺乳细胞效率仍需优化。", "tags": ["retron", "ssDNA", "HDR", "method"], "difficulty": "hard", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["retron", "逆转录子", "mcDNA", "原位供体"], "evidence_dois": [], "language": "zh"}
{"id": "S17", "question": "大规模基因组编辑可能引发的嵌合体(mosaicism)安全问题", "answer": "嵌合体问题: 1)体内编辑时不同细胞接受不同编辑结果(WT/编辑/大缺失/倒位); 2)HSC体外编辑也产生等位基因嵌合(不同dry HSC clone有不同编辑); 3)on-target嵌合: pure deletion vs inversion vs 大缺失→functional mosaic; 4)安全隐患: 部分clone可能获得p53 LOH等致癌事件→克隆竞争→恶性转化; 5)检测: 单细胞测序或克隆分析→评估编辑产物谱; 6)缓解: 提高编辑均一性(高效RNP+短暂窗口)、筛选高纯度编辑群体。", "tags": ["mosaicism", "clonal", "safety"], "difficulty": "hard", "question_type": "safety", "source": "expert_knowledge", "required_modules": ["safety_firewall", "retrieval"], "key_entities": ["嵌合体", "克隆", "等位基因", "大缺失", "单细胞"], "evidence_dois": [], "language": "zh"}
{"id": "S18", "question": "CRISPR编辑后染色质桥和micronuclei形成的安全风险", "answer": "机制: Cas9 DSB→大片段缺失或染色体重排→不完全修复→姐妹染色单体融合→有丝分裂时形成染色质桥(chromatin bridge)→桥断裂→染色体碎片无法被纺锤体正确分配→形成微核(micronuclei)→微核中DNA暴露于cGAS→触发慢性炎症cGAS-STING→且微核内基因组碎片化(chromothripsis)→可一步产生多重重排。检测: EdU+γH2AX荧光+ FISH→微核率应<1%。这是on-target切割的固有风险，非脱靶。", "tags": ["micronuclei", "chromothripsis", "on_target_risk", "safety"], "difficulty": "hard", "question_type": "safety", "source": "literature", "required_modules": ["safety_firewall", "retrieval"], "key_entities": ["微核", "染色质桥", "chromothripsis", "cGAS-STING"], "evidence_dois": [], "language": "zh"}
{"id": "M24", "question": "Cas12a(Cpf1)的crRNA加工和切割机制与Cas9有何不同？", "answer": "差异: 1)crRNA加工: Cas12a自身加工pre-crRNA array(无需tracrRNA和RNase III); Cas9需tracrRNA+RNase III加工; 2)PAM: Cas12a识别5'-TTTV(T-rich); Cas9识别3'-NGG; 3)切割: Cas12a仅用RuvC切割两条链→产生5'突出5nt粘性末端(stagger cut, 远离PAM 18/23位); Cas9用HNH+RuvC各切一条→产生平末端(PAM处3bp); 4)trans-cleavage: Cas12a激活后可非特异切割ssDNA(用于DETECTR诊断); Cas9无此活性; 5)多重: 天然crRNA array加工→单载体多重编辑更简单。", "tags": ["Cas12a", "Cpf1", "crRNA", "mechanism"], "difficulty": "hard", "question_type": "mechanism", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["Cas12a", "crRNA加工", "stagger cut", "trans-cleavage", "RuvC"], "evidence_dois": [], "language": "zh"}
{"id": "SD15", "question": "如何设计一个CRISPR筛选实验来发现肿瘤免疫逃逸的新机制？", "answer": "方案: 1)文库: 全基因组sgRNA文库(Brunello, ~77K sgRNAs, ~4 sgRNAs/gene); 2)细胞模型: 癌细胞系(如MC38/B16)构建Cas9稳转; 3)筛选: 感染文库(MOI<0.3, 500x覆盖)→与T cells/NK cells共培养→耐杀伤的存活细胞 vs input比较; 4)测序: PCR扩增sgRNA→NGS→MAGeCK/BAGEL2分析富集基因; 5)正筛选: 富集的sgRNA对应免疫逃逸必需基因(如果KO后更能逃逸→B2M, JAK1/2, IFNGR1等); 6)验证: 单基因验证KO→体内肿瘤模型+anti-PD1治疗→确认耐药。", "tags": ["CRISPR_screen", "immune", "strategy_design"], "difficulty": "hard", "question_type": "strategy_design", "source": "expert_knowledge", "required_modules": ["retrieval"], "key_entities": ["CRISPR筛选", "Brunello", "MAGeCK", "免疫逃逸", "T cells"], "evidence_dois": [], "language": "zh"}
{"id": "SD16", "question": "Design a strategy for in vivo lung-targeted CRISPR editing", "answer": "Strategy: 1) Target disease: CF (CFTR ΔF508) or lung cancer (KRAS G12D KO); 2) Delivery options: a) Nebulized LNP-mRNA (SORT LNP with DOTAP for lung tropism), b) Engineered AAV6.2FF (lung-tropic variant), c) Polymer-based NPs (PBAEs); 3) Route: intratracheal or nebulized inhalation; 4) Cell targets: airway basal cells (stem cells for durable effect) or alveolar epithelial cells; 5) Challenges: mucus barrier (add mucolytics like NAC), low basal cell transduction (<15%), immune response in lung; 6) Validation: reporter mice (Ai14) → tdTomato activation → flow cytometry/imaging →quantify cell types and percentage edited; 7) Dose escalation in NHP before human.", "tags": ["lung", "delivery", "nebulized", "strategy_design"], "difficulty": "hard", "question_type": "strategy_design", "source": "expert_knowledge", "required_modules": ["delivery_tree", "retrieval"], "key_entities": ["lung", "nebulized", "SORT LNP", "basal cells", "CF"], "evidence_dois": [], "language": "en"}
{"id": "C30", "question": "Cas13a(C2c2)和CasRx(Cas13d)在RNA编辑中的比较", "answer": "Cas13a(LshCas13a/LwaCas13a): 较大(~1300aa), collateral RNA cleavage较强(激活后切割周围RNA), 在哺乳细胞中KD效率~50-80%, 细胞毒性较高(collateral effect); 用于SHERLOCK诊断。CasRx(RfxCas13d): 最小(967aa→单AAV递送), collateral很低(哺乳细胞中几乎无), KD效率>90%, 细胞毒性极低; 更适合治疗应用。选择建议: 诊断→Cas13a(signal amplification via collateral); 治疗→CasRx(高效低毒); RNA成像→dCasRx。", "tags": ["Cas13a", "CasRx", "RNA", "comparison"], "difficulty": "hard", "question_type": "comparison", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["Cas13a", "CasRx", "collateral", "RNA knockdown"], "evidence_dois": [], "language": "zh"}
{"id": "F39", "question": "什么是Cas9 VLP(virus-like particle)递送？", "answer": "Cas9 VLP利用改造的病毒样颗粒(无病毒基因组)瞬时递送Cas9-sgRNA RNP。典型系统: 1)Gag-Cas9融合蛋白→组装进VLP; 2)sgRNA通过病毒包装信号共包装; 3)VSV-G假型化→广泛感染; 4)细胞内Cas9自蛋白酶切释放→编辑→24-48h降解。优势: 蛋白级递送(无DNA残留→无整合风险)、无持续表达、免疫原性低于AAV。代表: Naldini实验室babyLentiVLP、David Liu实验室eVLPs(2023 Cell)。适合: 对精确瞬时递送要求高的治疗场景。", "tags": ["VLP", "delivery", "transient"], "difficulty": "hard", "question_type": "factual", "source": "literature", "required_modules": ["delivery_tree", "retrieval"], "key_entities": ["VLP", "Gag-Cas9", "VSV-G", "eVLP", "瞬时递送"], "evidence_dois": [], "language": "zh"}
{"id": "F40", "question": "PEmax和epegRNA是什么？它们如何提升先导编辑效率？", "answer": "PEmax: David Liu团队2021年优化的PE2变体: 1)codon/NLS优化→核定位更强; 2)Rad51 DNA-binding domain融合→稳定3'flap; 3)逆转录酶M-MLV D200N/T330P/L603W/T306K/W313F五突变→RT processivity和热稳定性↑。效率: PE2→PEmax提升2-5x。epegRNA(engineered pegRNA): 3'延伸区添加tevoPreQ1/mpknot等RNA结构基序→保护pegRNA 3'端不被胞内核酸外切酶降解→效率提升3-5x。PEmax+epegRNA组合=PE5max→平均效率从PE2的~5%提升至~40-60%。", "tags": ["PEmax", "epegRNA", "prime_editing"], "difficulty": "hard", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["PEmax", "epegRNA", "tevoPreQ1", "M-MLV", "效率提升"], "evidence_dois": [], "language": "zh"}
{"id": "T16", "question": "表观基因组编辑(Epigenome Editing)的发展时间线", "answer": "2013: dCas9-KRAB首次实现CRISPRi基因沉默(Gilbert/Qi); 2014: dCas9-VP64/p65/Rta CRISPRa激活(Konermann); 2016: dCas9-DNMT3A靶向DNA甲基化(Vojta); 2016: dCas9-TET1靶向DNA去甲基化(Liu); 2017: dCas9-p300 CBP增强子激活(Hilton); 2021: CRISPRoff(DNMT3A-DNMT3L-KRAB融合)→单次给药永久沉默(Nuñez/Doudna); 2023: CRISPRoff体内验证→LNP递送至肝脏→基因持久沉默+可被CRISPRon逆转; 2024-2025: 表观基因组编辑进入临床前(Chroma Medicine等)。与DNA编辑的关键区别: 不改变序列→可逆→安全窗口更大。", "tags": ["epigenome", "CRISPRoff", "timeline"], "difficulty": "hard", "question_type": "temporal", "source": "literature", "required_modules": ["almanac", "retrieval"], "key_entities": ["CRISPRoff", "CRISPRi", "KRAB", "DNMT3A", "表观基因组"], "evidence_dois": [], "language": "zh"}
{"id": "T17", "question": "体内基因编辑临床试验从首次到获批的里程碑时间线", "answer": "2019: 首个体内CRISPR递送(EDIT-101, AAV到眼); 2020.03: NTLA-2001 Phase I首例给药(LNP到肝); 2021.06: NTLA-2001 NEJM发表→证明体内CRISPR安全有效; 2022: VERVE-101首例碱基编辑患者给药; 2022: EBT-101(HIV) AAV9系统给药; 2023: NTLA-2001 Phase II启动; 2023: NTLA-3001(HAE)Phase I数据发布; 2024: VERVE-101 Phase Ib扩展数据→LDL-C↓55%; 2025: 多个体内编辑Phase II/III在进行→预计2026-2027首个体内CRISPR获批(可能是NTLA-2001)。", "tags": ["in_vivo", "milestones", "timeline"], "difficulty": "medium", "question_type": "temporal", "source": "GEAlmanac", "required_modules": ["almanac", "retrieval"], "key_entities": ["EDIT-101", "NTLA-2001", "VERVE-101", "体内", "里程碑"], "evidence_dois": [], "language": "zh"}
{"id": "F41", "question": "什么是Bridge RNA重组系统？", "answer": "Bridge RNA(桥接RNA)是2024年Patrick Hsu团队在Nature发表的新型可编程基因组编辑系统。来源于IS110转座子家族。Bridge RNA同时编码靶标识别序列和供体识别序列→引导IS110重组酶在靶标和供体DNA之间进行可编程重组。可实现：插入、删除、倒位。与CRISPR不同点：不产生DSB,利用重组而非切割+修复。潜在优势：大片段操作无需DSB→更安全，可逆。目前处于早期阶段。", "tags": ["Bridge_RNA", "IS110", "recombination"], "difficulty": "hard", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["Bridge RNA", "IS110", "重组酶", "Patrick Hsu"], "evidence_dois": [], "language": "zh"}
{"id": "F42", "question": "什么是DTECT(Dinucleotide signalTEmplate Captured Translocation)？", "answer": "DTECT是检测CRISPR编辑产生的大片段结构变异(SV)的方法。原理：DSB修复可产生染色体易位→DTECT使用PCR引物对不同染色体断裂位点→如果发生易位→PCR可扩增→NGS定量。用途：评估多重CRISPR编辑中不同靶位点间的易位频率。已有检测表明Cas9多重编辑易位率0.01-1%→安全评估必需。", "tags": ["DTECT", "translocation", "safety_detection"], "difficulty": "hard", "question_type": "factual", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["DTECT", "易位", "结构变异", "多重编辑"], "evidence_dois": [], "language": "zh"}
{"id": "C31", "question": "比较碱基编辑和先导编辑在点突变纠正中的优劣", "answer": "碱基编辑(BE): 优势→效率高(50-70%)、递送简单(单gRNA)、成熟度高(已进入临床); 劣势→仅限4种转换(C→T/A→G)、编辑窗口内旁观者编辑、PAM限制位点选择。先导编辑(PE): 优势→理论上任意点突变/小插入/小缺失、无旁观者、精确到单碱基; 劣势→效率低(5-30%,PEmax+epegRNA可达50%)、组分复杂(pegRNA设计难)、递送挑战(PE融合蛋白很大~6.8kb)。选择原则：如果突变可用BE→优先BE(效率+简单); BE不可达→用PE。", "tags": ["base_editing", "prime_editing", "point_mutation", "comparison"], "difficulty": "medium", "question_type": "comparison", "source": "literature", "required_modules": ["retrieval", "variant_resolver"], "key_entities": ["碱基编辑", "先导编辑", "效率", "旁观者", "递送"], "evidence_dois": [], "language": "zh"}
{"id": "C32", "question": "ex vivo vs in vivo基因编辑治疗模式的比较", "answer": "Ex vivo: 取出细胞→体外编辑→质控→回输。优势: 编辑效率可控(编辑后检测、筛选)、安全性可验证(测脱靶后再回输)、免疫原性低(自体细胞); 劣势: 需要清髓预处理(毒性大)、流程复杂(3-4周)、成本极高(个体化)、仅限可取出/回输的细胞(HSC、T细胞)。In vivo: 直接给药编辑体内细胞。优势: 一次注射(简单)、可达不可取出的器官(肝、眼、脑)、规模化生产→成本可降; 劣势: 编辑效率不可预检、全身暴露→脱靶风险高、免疫反应。趋势: 长期看in vivo将成主流(可及性)。", "tags": ["ex_vivo", "in_vivo", "comparison"], "difficulty": "medium", "question_type": "comparison", "source": "expert_knowledge", "required_modules": ["retrieval"], "key_entities": ["ex vivo", "in vivo", "清髓", "一次注射", "成本"], "evidence_dois": [], "language": "zh"}
{"id": "M25", "question": "CRISPR转录调控中KRAB结构域介导沉默的机制", "answer": "机制: dCas9-KRAB融合蛋白→KRAB招募KAP1(TRIM28)→KAP1进一步招募: 1)NuRD复合物(组蛋白去乙酰化→H3K27ac↓); 2)SETDB1甲基转移酶(H3K9me3)→形成异染色质; 3)HP1α/β识别H3K9me3→spreading; 4)DNMT3A/3B(DNA甲基化, CRISPRoff中增强)。效果: 靶基因周围形成~1-2kb沉默域→转录因子无法结合→基因关闭。CRISPRoff(KRAB+DNMT3A+DNMT3L三融合)可将沉默变为永久(DNA甲基化跨细胞分裂维持)。", "tags": ["KRAB", "CRISPRi", "epigenetic_silencing", "mechanism"], "difficulty": "hard", "question_type": "mechanism", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["KRAB", "KAP1", "H3K9me3", "SETDB1", "CRISPRoff"], "evidence_dois": [], "language": "zh"}
{"id": "CL25", "question": "nex-z(zenrelimab+CRISPR编辑NK细胞)在实体瘤临床试验中的探索", "answer": "方向: CRISPR编辑NK细胞(iPSC来源)→KO CISH(增强细胞因子信号)+KO B2M(逃避T细胞)→加入CD19/Mesothelin CAR→联合PD-L1抗体(zenrelimab)。临床: FT516/FT596(Fate Therapeutics)→iPSC-NK+CD16a高亲和力+IL-15 receptor→Phase I淋巴瘤/实体瘤→与抗体联合ADCC增强。挑战: NK体内持续时间短(2-4周)→需多次给药; CRISPR编辑后NK扩增困难。2024状态: 多个iPSC-NK Phase I/II进行中。", "tags": ["NK_cell", "CRISPR", "solid_tumor", "clinical"], "difficulty": "hard", "question_type": "clinical", "source": "literature", "required_modules": ["almanac", "retrieval"], "key_entities": ["NK细胞", "iPSC", "CISH", "CAR-NK", "实体瘤"], "evidence_dois": [], "language": "zh"}
{"id": "S19", "question": "CRISPR基因编辑的知情同意中应特别告知患者的风险", "answer": "知情同意要点: 1)脱靶编辑→可能影响其他基因→远期致癌风险(尽管目前临床试验未观察到); 2)大片段缺失/染色体重排→on-target位点非预期结果; 3)嵌合编辑→体内部分细胞未被编辑→疗效不确定; 4)免疫反应→抗Cas9抗体/T细胞; 5)长期未知→基因编辑<10年临床经验→超长期安全性未知; 6)不可逆性→DNA编辑一旦发生无法撤回(区别于药物停药); 7)生殖传递→如果编辑涉及生殖细胞(应避免但理论可能)→遗传后代。患者应签署长期随访协议(≥15年)。", "tags": ["informed_consent", "ethics", "safety"], "difficulty": "medium", "question_type": "safety", "source": "expert_knowledge", "required_modules": ["safety_firewall", "retrieval"], "key_entities": ["知情同意", "脱靶", "不可逆", "长期随访", "伦理"], "evidence_dois": [], "language": "zh"}
{"id": "MH16", "question": "从CRISPR诊断(SHERLOCK/DETECTR)到治疗的技术转化路径", "answer": "技术转化: 1)SHERLOCK(2017,Cas13a): 恒温扩增+Cas13 collateral→fM灵敏度→COVID快检获EUA; DETECTR(2018,Cas12a): RPA+Cas12a→类似; 2)诊断验证了CRISPR在人类样本中的可靠性→建立公众信任; 3)诊断中发现的Cas变体反哺治疗: 如高保真Cas12a变体; 4)检测技术直接用于治疗QC: 基于Cas13的RNA检测可监测编辑产物表达; 5)商业路径: Sherlock Bio→诊断公司; Mammoth Bio→诊断起步→扩展至治疗; 6)监管: 诊断IVD vs治疗BLA完全不同监管路径。", "tags": ["SHERLOCK", "DETECTR", "diagnostics", "multi_hop"], "difficulty": "hard", "question_type": "multi_hop", "source": "literature", "required_modules": ["almanac", "retrieval"], "key_entities": ["SHERLOCK", "DETECTR", "Cas13a", "Cas12a", "诊断"], "evidence_dois": [], "language": "zh"}
{"id": "T18", "question": "CRISPR体外基因编辑治疗(ex vivo)获批时间线", "answer": "2019: Vertex/CRISPR CTX001(后更名Casgevy)Phase I首例SCD患者(Victoria Gray)给药; 2020-2022: Phase I/II持续入组→SCD+TDT→数据惊艳(HbF>20%/Hb>11g/dL); 2022.11: BLA提交; 2023.06: FDA ODAC一致推荐; 2023.11.16: UK MHRA全球首批Casgevy(SCD); 2023.12.08: FDA批准Casgevy(SCD); 2024.01: FDA批准Casgevy(TDT); 2024: EMA批准; 2024-2025: Casgevy商业化启动→全球定价~220万美元; 后续: CTX112/CTX131(异体CAR-T)推进Phase I。", "tags": ["Casgevy", "ex_vivo", "FDA", "timeline"], "difficulty": "medium", "question_type": "temporal", "source": "GEAlmanac", "required_modules": ["almanac", "retrieval"], "key_entities": ["Casgevy", "Victoria Gray", "FDA", "MHRA", "ex vivo"], "evidence_dois": [], "language": "zh"}
{"id": "SD17", "question": "如何设计利用CRISPR打靶BCL11A增强子治疗β-地中海贫血的方案？", "answer": "方案: 1)靶标确认: BCL11A +58区域红系特异性增强子(GATA1结合位点); 2)sgRNA: 靶向+58内GATA1 motif→破坏增强子→BCL11A在红系中下调→γ-珠蛋白去抑制→HbF↑; 3)编辑: CD34+ HSC动员采集(Plerixafor)→RNP电穿孔(MaxCyte/Lonza)→培养48h; 4)质控: 编辑效率>80%(Amp-seq)、脱靶<0.1%(GUIDE-seq)、集落形成(CFU)正常; 5)预处理: 白消安清髓(AUC 80-100mg*h/L, 4天); 6)回输: IV; 7)监测: CBC+HbF电泳+甲基纤维素CFU→评估嵌合和编辑持久性。即Casgevy方案的复现。", "tags": ["BCL11A", "thalassemia", "ex_vivo", "strategy_design"], "difficulty": "hard", "question_type": "strategy_design", "source": "GEAlmanac", "required_modules": ["almanac", "variant_resolver", "retrieval"], "key_entities": ["BCL11A", "+58增强子", "CD34+", "白消安", "HbF"], "evidence_dois": [], "language": "zh"}
{"id": "F43", "question": "什么是IND-enabling研究？基因编辑疗法需要哪些关键研究？", "answer": "IND(Investigational New Drug)-enabling studies是向FDA/NMPA提交临床试验申请前的必需研究。基因编辑疗法关键IND研究: 1)药效: 动物模型编辑效率+功能纠正; 2)体内分布: 编辑器在各器官的分布(qPCR/ddPCR); 3)脱靶: 全基因组分析(GUIDE-seq/CIRCLE-seq)+amplicon验证; 4)毒理: GLP合规, 2种动物(啮齿+NHP), 急性+长期(6-12月), 组织病理; 5)免疫原性: 抗Cas9抗体+T细胞反应; 6)CMC: GMP级生产工艺+质量控制; 7)致癌性: 如需长期表达则需(AAV); 8)生殖毒性: 如系统给药。", "tags": ["IND", "regulatory", "preclinical"], "difficulty": "medium", "question_type": "factual", "source": "expert_knowledge", "required_modules": ["retrieval"], "key_entities": ["IND", "GLP", "毒理", "脱靶", "GMP"], "evidence_dois": [], "language": "zh"}
{"id": "F44", "question": "GalNAc-conjugated ASO是什么？与LNP递送有什么区别？", "answer": "GalNAc(N-乙酰半乳糖胺)偶联ASO: GalNAc与ASGPR(肝细胞表面受体)高亲和力结合→受体介导内吞→ASO进入肝细胞。ASO可以是反义寡核苷酸(gapmer)或siRNA。与LNP区别: 1)GalNAc皮下注射→LNP IV注射; 2)GalNAc分子量小、稳定→无需冷链;LNP是脂质纳米颗粒,需冷链; 3)GalNAc每月/季度给药→LNP基因编辑一次性; 4)GalNAc不可递送大分子(如mRNA)→LNP可包裹mRNA; 5)成本: GalNAc-ASO年费用数万美元→基因编辑一次性百万美元。", "tags": ["GalNAc", "ASO", "LNP", "delivery"], "difficulty": "medium", "question_type": "factual", "source": "literature", "required_modules": ["delivery_tree", "retrieval"], "key_entities": ["GalNAc", "ASGPR", "ASO", "肝脏", "递送"], "evidence_dois": [], "language": "zh"}
{"id": "M26", "question": "HDR中RAD51核蛋白丝形成的分子机制", "answer": "机制: DSB产生→MRN复合物(MRE11-RAD50-NBS1)+CtIP在5'→3'方向切除→产生3'单链DNA(ssDNA)突出; RPA首先包被ssDNA(防止二级结构); BRCA2介导RAD51替换RPA→RAD51以6个单体为单位螺旋缠绕ssDNA→形成核蛋白丝(presynaptic filament); RAD51丝在姐妹染色单体中搜索同源序列→链侵入(D-loop)→DNA聚合酶以同源模板合成→Holliday junction形成→分解。i53抑制53BP1→促进切除→更多RAD51丝→更多HDR。", "tags": ["RAD51", "HDR", "DNA_repair", "mechanism"], "difficulty": "hard", "question_type": "mechanism", "source": "literature", "required_modules": ["retrieval"], "key_entities": ["RAD51", "RPA", "BRCA2", "核蛋白丝", "链侵入"], "evidence_dois": [], "language": "zh"}
{"id": "S20", "question": "What are the risks of AAV integration after CRISPR-AAV delivery?", "answer": "Risks: 1) AAV was considered non-integrating, but recent studies show ~0.1-1% integration rate at DSB sites created by Cas9; 2) AAV-ITR integration can cause insertional mutagenesis→hepatocellular carcinoma observed in neonatal mice (Chandler 2015); 3) Cas9 DSB creates a hotspot for AAV fragment capture→persistent Cas9 expression worsens this; 4) Large deletions at integration sites→potential loss of tumor suppressor; 5) Mitigation: use RNP or mRNA delivery to avoid persistent expression, use integration-deficient AAV variants, monitor clonal expansion by IS analysis; 6) Regulatory: FDA requires long-term (15-year) follow-up for all AAV gene therapy patients.", "tags": ["AAV", "integration", "safety"], "difficulty": "hard", "question_type": "safety", "source": "literature", "required_modules": ["safety_firewall", "delivery_tree", "retrieval"], "key_entities": ["AAV integration", "ITR", "insertional mutagenesis", "HCC", "长期随访"], "evidence_dois": [], "language": "en"}
{"id": "C33", "question": "比较CRISPR基因编辑与传统基因治疗(基因添加)的优劣", "answer": "基因添加: 通过AAV/LV递送功能基因拷贝→不修改内源基因。优势: 简单(只需一个表达盒)、已有多个获批产品(Luxturna/Zolgensma); 劣势: 需持续表达(AAV)或整合(LV→插入致突变)、载荷受限(AAV<4.7kb)、不能修复显性负效应突变。基因编辑: 修改/修复内源基因。优势: 利用内源调控→生理表达、可处理显性负效应(KO突变等位基因)、一次性→无需持续表达; 劣势: 编辑效率问题、脱靶风险、递送编辑器更复杂。趋势: 基因编辑逐步取代基因添加成为主流。", "tags": ["gene_therapy", "gene_editing", "comparison"], "difficulty": "medium", "question_type": "comparison", "source": "expert_knowledge", "required_modules": ["retrieval"], "key_entities": ["基因添加", "基因编辑", "AAV", "整合", "显性负效应"], "evidence_dois": [], "language": "zh"}
{"id": "T19", "question": "CRISPR知识产权纠纷时间线", "answer": "2012: Broad/Zhang Feng提交美国临时专利(eukaryotic CRISPR); 2012.05: Doudna/Charpentier提交PCT申请(in vitro CRISPR); 2014: Broad获得首批美国CRISPR专利(加速审查); 2017: USPTO PTAB裁定Broad/Zhang专利与Doudna/Charpentier无干涉→Broad专利有效; 2018: EPO撤销Broad部分欧洲专利(优先权问题); 2022: USPTO新interference→PTAB裁定Broad先发明真核细胞CRISPR→Broad再次胜出; 2023-2025: 全球专利格局: Broad/MIT在美国占优, UC Berkeley在欧洲和其他地区有更强position。商业许可: Editas(Broad) vs Intellia/CRISPR Tx(UC/Vienna)。", "tags": ["patent", "IP", "timeline"], "difficulty": "medium", "question_type": "temporal", "source": "expert_knowledge", "required_modules": ["patent", "retrieval"], "key_entities": ["Broad", "UC Berkeley", "专利", "PTAB", "知识产权"], "evidence_dois": [], "language": "zh"}
